26/04/2021

Date Journal Title Study type Country Authors Link Trial identifier Intervention Main question https://www.thelancet.c To evaluate the efficacy of the Inhaled budesonide in the treatment of early om/journals/lanres/artic Lancet Ramakrishnan S., inhaled glucocorticoid widely used inhaled glucocorticoid 9‐Apr‐21 COVID 19 (STOIC): a phase 2, open‐label, RCT 2 phase UK le/PIIS2213‐ NCT04416399 Respir Med. et al. budesonide budesonide in individuals with early randomised controlled trial 2600(21)00160‐ COVID‐19 in the community. 0/fulltext https://www.thelancet.c Efficacy of ChAdOx1 nCoV19 (AZD1222) vaccine post‐hoc analysis of the efficacy of om/journals/lancet/artic against SARS‐CoV‐2 variant of concern 202012/01 Emary K.R.W., et ChAdOx1 nCoV 19 the adenoviral vector vaccine, 30‐Mar‐21 Lancet vaccine UK le/PIIS0140‐ NCT04400838 (B.1.1.7): an exploratory analysis of a randomised al (AZD1222) vaccine ChAdOx1 nCoV‐19 (AZD1222), 6736(21)00628‐ controlled trial against the variant B.1.1.7. 0/fulltext Methylprednisolone or dexamethasone, which https://bmcinfectdis.bio To assess the effectiveness of BMC one is superior corticosteroid in the treatment of medcentral.com/articles IRCT20200204046 Methylprednisolone methylprednisolone treatment 10‐Apr‐21 Infectious RCT Iran Ranjbar B hospitalized COVID‐19 patients: a triple‐blinded /10.1186/s12879‐021‐ 369N1 or dexamethason versus dexamethasone for Diseases randomized controlled trial 06045‐3 hospitalized COVID‐19 patients.

Two phase 1 and phase 2 randomized, Immunogenicity and Safety of a SARS-CoV-2 https://www.medrxiv.or To report the immunogenicity and double‐ NCT04758273 Inactivated Vaccine (KCONVAC) in Healthy g/content/10.1101/2021 safety of a SARS‐CoV‐2 inactivated 8‐Apr‐2021 MedRxiv blind, and China Pan H et al AND KCONVAC Adults: Two Randomized, Double-blind, and .04.07.21253850v1.full.p vaccine, KCONVAC, in healthy placebo‐ NCT04756323 Placebo-controlled Phase 1/2 Clinical Trials df adults. controlled trials of KCONVAC

INTERIM REPORT: SAFETY AND Interim https://www.medrxiv.or IMMUNOGENICITY OF AN INACTIVATED To evaluate safety parameters and analysis of a g/content/10.1101/2021 1‐Apr‐2021 MedRxiv VACCINE AGAINST SARS-COV-2 IN Chile Bueno SM et al NCT04651790 CoronaVac immunogenicity against SARS‐CoV‐2 multicenter .03.31.21254494v1.full.p HEALTHY CHILEAN ADULTS IN A PHASE 3 after immunization with CoronaVac phase 3 CT df CLINICAL TRIAL

To assess the effect of oral Ivermectin treatment, which has been associated with iota‐ carrageenan in repeated doses A RANDOMIZED TRIAL - INTENSIVE https://www.medrxiv.or through the nasal and TREATMENT BASED IN IVERMECTIN AND g/content/10.1101/2021 Ivermectin / oral topical route, on the 30‐Mar‐2021 MedRxiv IOTA-CARRAGEENAN AS PRE-EXPOSURE RCT Argentina Chahla RE et al NCT04701710 .03.26.21254398v1.full.p IotaCarrageenan appearance and eventual PROPHYLAXIS FOR COVID- 19 IN df progression of COVID‐19 disease in HEALTHCARE AGENTS a healthy population that are exposed to it and have a higher risk of contagion of SARS‐ COV‐2 To assess the use of a nasal spray Efficacy of a nasal spray containing Iota‐ https://www.medrxiv.or Nasal spray containing containing I‐C in the prophylaxis of Carrageenan in the prophylaxis of COVID‐ 19 CARR‐COV2 Trial g/content/10.1101/2021 Iota‐Carrageenan (I‐C) 15‐Apr‐2021 MedRxiv RCT Argentina NCT04521322 COVID‐19 in hospital personnel in hospital personnel dedicated to patients Group collaborators .04.13.21255409v1.full.p or placebo for 21 dedicated to care of COVID‐19 df days. care with COVID‐19 disease patients to report the occurrence of https://www.medrxiv.or Performance of vaccination with CoronaVac symptomatic COVID‐19 in a cohort preliminary g/content/10.1101/2021 15‐Apr‐2021 MedRxiv in a cohort of healthcare workers (HCW) ‐ Brazil De Faria E et al NA CoronaVac of healthcare workers (HCW) report .04.12.21255308v1.full.p vaccinated with CoronaVac and to preliminary report df estimate its effectiveness.

RBD‐specific polyclonal F(ab )2 fragments of To analyze the safety and efficacy of equine antibodies in patients with moderate to https://www.ncbi.nlm.ni EClinicalMedi Equine poly‐ clonal specific anti SARS‐COV‐2 EpAbs in 8‐Apr‐2021 severe COVID‐19 disease: A randomized, RCT Argentina Lopardo et al h.gov/pmc/articles/PMC NCT04494984 cine antibodies (EpAbs) hospitalized patients with mod‐ multicenter, double‐blind, placebo‐controlled, 8037439/pdf/main.pdf erate and severe COVID‐19 disease adaptive phase 2/3 clinical trial

Diphenhydramine Compound (Diphenhydramine + Quaternary ammonium compounds Int J of Effect of Ammonium Chloride in addition to https://pubmed.ncbi.nl Ammonium Chloride) have been demonstrated to have 12‐Apr‐2021 Infectious standard of care in outpatients and hospitalized RCT Iran Siami Z et al NA m.nih.gov/33878462/ plus standard of care antiviral effects and may be of use Diseases COVID‐19 patients: a randomized clinical trial or Diphenhydramine against SARS‐CoV‐2 infections. alone and standard of care groups

To determine any possible effects and safety concerns of the two most https://www.nature.co Scientific Role of interferon therapy in severe COVID‐19: promising exogenously 13‐Apr‐2021 RCT Iran Darazam IA et al m/articles/s41598‐021‐ NCT04343768 IFNβ1a and IFNβ1b reports the COVIFERON randomized controlled trial administrable IFNs on the course 86859‐y and outcomes of patients hospitalized with severe COVID‐19. Peginterferon Lambda‐1a for treatment of To evaluate the efficacy of Lambda https://pubmed.ncbi.nl Peginterferon Lambda‐ 30‐Mar‐2021 Nature Comm outpatients with uncomplicated COVID‐19: a RCT USA Jagannathan P et al NCT04331899 in reducing the duration of viral m.nih.gov/33785743/ 1a randomized placebo‐controlled trial shedding in outpatients. https://www.thelancet.c Safety and immunogenicity of SARS‐CoV‐2 The Lancet om/journals/laninf/articl recombinant protein vaccine formulations in healthy Vaccine trial Safety and imunogenicity of CoV2 preS 19‐Apr‐21 Infectious Multinational Goepfert et al. e/PIIS1473‐ NCT04537208 CoV2 preS dTM vaccine adults: a randomised, placebo‐controlled, dose‐ranging phase I/II dTM vaccine Disease study 3099(21)00147‐ X/fulltext https://www.thelancet.c Safety and immunogenicity of an MF59‐ The Lancet om/journals/laninf/articl adjuvanted spike glycoprotein‐clamp vaccine for Vaccine trial MF59‐adjuvanted Safety and imunogenicity of MF59‐ 19‐Apr‐21 Infectious Australia Chappell et al. e/PIIS1473‐ NCT04495933 SARS‐CoV‐2: a randomised, double‐blind, placebo‐ phase I subunit vaccine adjuvanted subunit vaccine Disease 3099(21)00200‐ controlled, phase 1 trial 0/fulltext ZF2001 Vaccine ‐ protein subunit Safety and immunogenicity of a recombinant vaccine against COVID‐ To assess the safety and https://www.sciencedire The Lancet tandem‐repeat dimeric RBD‐based protein 19 using a dimeric immunogenicity of this vaccine, ct.com/science/articleS1 24‐Mar‐21 Infectious subunit vaccine (ZF2001) against COVID‐19 in vaccine ‐ pha China ShilongYang, et al. 445194 and NCT044 form of the receptor‐ ZF2001, and determine the 473309921001274/pii/? Diseases adults: two randomised, double‐blind, placebo‐ binding domain (RBD) appropriate dose and schedule for via%3Dihub controlled, phase 1 and 2 trials of the SARS‐CoV‐2 an efficacy study. spike protein as the antigen

Clinical effectiveness of drugs in hospitalized https://journals.sagepub To assess the clinical effectiveness 25‐Mar‐21 dvances in Resp patients with COVID‐19: a systematic review and meta‐analysis Mexico Zuñiga RAA, et al. .com/doi/10.1177/1753 NA ne, lopinavir, ritonavir, of drugs used in hospitalized meta‐analysis 4666211007214 patients with COVID‐19 infection. Effect of Helmet Noninvasive Ventilation vs High‐ To assess whether helmet Flow Nasal Oxygen on Days Free of Respiratory https://jamanetwork.co noninvasive ventilation can increase 25‐Mar‐21 JAMA Support in Patients With COVID‐19 and Moderate RCT International Domenico Luca Griecom/journals/jama/fullarti NCT04502576 oxygen the days free of respiratory support to Severe Hypoxemic Respiratory Failure The cle/2778088 in patients with COVID‐19 compared HENIVOT Randomized Clinical Trial with high‐flow nasal oxygen alone.

Effect of Intermediate‐Dose vs Standard‐Dose To evaluate the effects of Prophylactic Anticoagulation on Thrombotic https://jamanetwork.co intermediate‐dose vs standard‐dose Events, Extracorporeal Membrane Oxygenation 18‐Mar‐21 JAMA RCT Iran SPIRATION Investigatom/journals/jama/fullarti NCT04486508 dard prophylactic antico prophylactic anticoagulation among Treatment, or Mortality Among Patients With cle/2777829 patients with COVID‐19 admitted to COVID‐19 Admitted to the Intensive Care Unit the intensive care unit (ICU) The INSPIRATION Randomized Clinical Trial

Safety and immunogenicity of an inactivated https://www.thelancet.c SARS‐CoV‐2 vaccine, BBV152: interim results om/journals/laninf/articl To evaluate the safety and Lancet Infect Vaccine trial BBV152 (Bharat 8‐Mar‐2021 from a double blind, randomised, mulcentre, India Ella R., et al. e/PIIS1473‐ NCT04471519 immunogenicity of an inactivated Dis Phase II Biotech) vaccine phase 2 trial, and 3‐month follow‐up of a double‐ 3099(21)00070‐ SARS‐CoV‐2 vaccine, BBV152. blind, randomised phase 1 trial 0/fulltext Effect of Ivermectin on Time to Resolution of https://jamanetwork.co To determine whether ivermectin is RCT Phase Lopez‐Medina E., 4‐Mar‐2021 JAMA Symptoms Among Adults With Mild COVID‐19A Colombia/USA m/journals/jama/fullarti NCT04405843 Ivermectin an efficacious treatment for mild III et al. Randomized Clinical Trial cle/2777389 COVID‐19. To assess safety and efficacy of sarilumab, an interleukin‐6 receptor https://www.thelancet.c inhibitor, in patients with severe Sarilumab in patients admitted to hospital with om/journals/lanres/artic (requiring supplemental oxygen by Lancet Respir RCT Phase 4‐Mar‐2021 severe or crical COVID 19: a randomised, International Lescure FX., et al. le/PIIS2213‐ NCT04327388 Sarilumab nasal cannula or face mask) or Med III double blind, placebo‐controlled, phase 3 trial 2600(21)00099‐ critical (requiring greater 0/fulltext supplemental oxygen, mechanical ventilation, or extracorporeal support) COVID‐19. Azithromycin for community treatment of https://www.thelancet.c To assess the effectiveness of suspected COVID‐19 in people at increased risk of PRINCIPLE Trial om/journals/lancet/artic azithromycin to treat suspected RCT Phase 4‐Mar‐2021 Lancet an adverse clinical course in the UK (PRINCIPLE): UK Collaborative le/PIIS0140‐ ISRCTN86534580 Azithromycin COVID‐19 among people in the III a randomised, controlled, open‐label, adaptive Group 6736(21)00461‐ community who had an increased platform trial X/fulltext risk of complications. Molnupiravir, EIDD‐ Single and multiple doses of 2801/MK‐4482, molnupiravir were evaluated in this prodrug of the active first‐in‐human, phase 1, Antimicrob Human Safety, Tolerability, and Pharmacokinetics https://aac.asm.org/con antiviral randomized, double‐blind, 1‐Mar‐2021 Agents of Molnupiravir, a Novel Broad‐Spectrum Oral RCT Phase I USA Painter W. P., et al. tent/early/2021/02/24/ NCT04392219 ribonucleoside analog placebocontrolled study in healthy Chemother Anviral Agent with Acvity Against SARS‐CoV 2 AAC.02428‐20 14ß‐d‐N4‐ volunteers, which included hydroxycytidine (NHC; evaluation of the effect of food on EIDD‐1931) pharmacokinetics.

To evaluate the immunogenicity of the Ad26.COV2.S vaccine Immunogenicity of the (Janssen/Johnson & Johnson) in Immunogenicity of the Ad26.COV2.S Vaccine for Vaccine trial Kathryn E. Ad26.COV2.S Vaccine for Ad26.COV2.S Vaccine 11‐Mar‐2021 JAMA USA NCT04436276 humans, including the kinetics, COVID‐19 Phase I Stephenson COVID‐19 | Vaccination (Janssen) magnitude, and phenotype of SARS‐ | JAMA | JAMA Network CoV‐2 spike‐specific humoral and cellular immune responses.

To assess the efficacy and safety of Signal Effect of human umbilical cord‐derived Human umbilical cord‐ human umbilical cord‐mesenchymal Transduct mesenchymal stem cells on lung damage in Vaccine trial https://pubmed.ncbi.nl 10‐Feb‐2021 China Shi et el. NCT04288102 derived mesenchymal stem cells (UC‐MSCs) to treat severe Target Ther severe COVID‐19 patients: a randomized, double‐ Phase I/II m.nih.gov/33568628/ stem cells COVID‐19 patients with lung blind, placebo‐controlled phase 2 trial damage, based on our phase 1 data.

A preliminary report of a randomized controlled To evaluate the safety and A preliminary report of a randomized controlled phase 2 trial of the immunogenicity of vaccine 9‐Feb‐2021 Vaccine phase 2 trial of the safety and immunogenicity of RCT phase II US LaurenceChu safety and NCT04405076 mRNA‐1273 vaccine candidate mRNA‐1273, encoding mRNA‐1273 SARS‐CoV‐2 vaccine immunogenicity of the prefusion‐stabilized spike mRNA‐1273 SARS‐CoV‐2 protein of SARS‐CoV‐2. vaccine ‐ ScienceDirect https://www.ncbi.nlm.ni Early versus deferred anti‐SARS‐CoV‐2 To evaluate the efficacy and safety h.gov/pmc/articles/PMC 03‐Mar‐21 Plos Med convalescent plasma in patients admitted for RCT Chile Balcells MA et al NCT04375098 Convalescent Plasma of early Convalescent Plasma 7929568/pdf/pmed.100 COVID‐19: A randomized phase II clinical trial therapy in COVID-19 progression 3415.pdf Oral dose of Thrombosis Sulodexide in the treatment of patients with To evaluate the effect of sulodexide Gonzalez Ochoa AJ https://pubmed.ncbi.nl sulodexide (500 LRU 07‐Mar‐21 and early stages of COVID‐19: a randomized RCT Mexico ISRCTN59048638 when used in the early clinical et al m.nih.gov/33677827/ twice a day) or Haemostasis controlled trial stages of COVID‐19 placebo for 21 days To assess the safety and efficacy of https://www.nejm.org/d the ChAdOx1 nCoV‐19 vaccine Efficacy of the ChAdOx1 nCoV‐19 Covid‐19 oi/pdf/10.1056/NEJMoa ChAdOx1 nCoV‐19 16‐Mar‐21 NEJM RCT South Africa Madhi SA et al NCT04444674 (AZD1222) in people not infected Vaccine against the B.1.351 Variant 2102214?articleTools=tr vaccine (AZD1222) with the human immunodeficiency ue virus (HIV) in South Africa.

https://www.nejm.org/d Evaluation of the effectiveness of the BNT162b2 mRNA Covid‐19 Vaccine in a Nationwide BNT162b2 mRNA Covid‐ BNT162b2 mRNA vaccine based on data 24‐Feb‐21 NEJM Vaccine Israel Dagan N., et al. oi/10.1056/NEJMoa2101 NA Mass Vaccination Setting 19 Vaccine from Israel’s largest health care 765 organization. Exploratory analyses of the impact on https://www.thelancet.c immunogenicity and efficacy of Single‐dose administration and the influence of the om/journals/lancet/artic extending the interval between priming timing of the booster dose on immunogenicity and ChAdOx1 nCoV‐19 19‐Feb‐21 Lancet Vaccine UK Voysey M., et al. le/PIIS0140‐ NA and booster doses. efficacy of ChAdOx1 nCoV19 (AZD1222) vaccine: a vaccine ‐ Immunogenicity and protection pooled analysis of four randomised trials 6736(21)00432‐ 3/fulltext afforded by the first dose, before a booster dose has been offered. https://www.thelancet.c om/journals/lancet/artic To examine early reductions in SARS‐ Early rate reductions of SARS‐CoV‐2 infection and 18‐Feb‐21 Lancet Vaccine Israel Amit S., et al. le/PIIS0140‐ NA BNT162b2 vaccine CoV‐2 infection and COVID19 rates in COVID‐19 in BNT162b2 vaccine recipients 6736(21)00448‐ vaccinated HCWs. 7/fulltext Association of Convalescent Plasma Treatment With https://jamanetwork.co Is treatment with convalescent plasma 28‐Feb‐21 JAMA Clinical Outcomes in Patients With COVID‐19 A Metaanalysis International Janiaud et al. m/journals/jama/fullarti NA convalescent plasma associated with improved clinical Systematic Review and Meta‐analysis cle/2777060 outcomes?

Effect of a Single High Dose of Vitamin D3 on Hospital Length of Stay in Patients With Effect of a Single High Dose of Vitamin D3 on Hospital To investigate the effect of a single high Moderate to Severe 17‐Feb‐21 JAMA Length of Stay in Patients With Moderate to Severe RCT Brazil Murai et al. NCT04449718 Vitamin D3 dose of vitamin D3 on hospital length of COVID‐19: A COVID‐19. A Randomized Clinical Trial stay in patients with COVID‐19. Randomized Clinical Trial | Complementary and Alternative Medicine | JAMA | JAMA Network To examine whether high‐dose zinc Effect of High‐Dose Zinc and Ascorbic Acid https://jamanetwork.co Zinc gluconate (50 mg), and/or high‐dose ascorbic acid reduce Supplementation vs Usual Care on Symptom Length m/journals/jamanetwor ascorbic acid (8000 mg), the severity or duration of symptoms 12‐Feb‐21 JAMA and Reduction Among Ambulatory Patients With SARS‐ RCT US Thomas et al. NCT04342728 kopen/fullarticle/277630 both agents, or standard compared with usual care among CoV‐2 Infection of care. ambulatory patients with SARS‐CoV‐2 The COVID A to Z Randomized Clinical Trial 5 infection. https://jamanetwork.co Whether nasopharyngeal application of Povidone Iodine Mouthwash, Gargle, and Nasal Spray m/journals/jamaotolary Povidone iodine (PI) PI could reduce the viral load of patients 4‐Feb‐21 JAMA to Reduce Nasopharyngeal Viral Load in Patients With RCT France Guenezan NCT04371965 ngology/fullarticle/2775 solutions. with nonsevere coronavirus disease COVID‐19. A Randomized Clinical Trial 984 2019 (COVID‐19) symptoms. Early Use of Corticosteroid May Prolong SARS‐CoV‐2 Efficacy and safety of corticosteroid Shedding in Non‐Intensive Care Unit Patients with https://pubmed.ncbi.nlm.ni 22‐Jan‐21 Respiration RCT China Tang et al. NCT04273321 methylprednisolone given to the hospitalized patients with COVID‐19 Pneumonia: A Multicenter, Single‐Blind, h.gov/33486496/ COVID‐19 Randomized Control Trial https://erj.ersjournals.com/ European Early use of nitazoxanide in mild Covid‐19 disease: content/erj/early/2021/01/ Efficacy and safety of nitrazoxanide in Jan‐21 Respiratory RCT Brazil Rocco et al. NCT04552483 nitazoxanide randomised, placebo‐controlled trial 04/13993003.03725‐ COVID‐19 patients Journal 2020.full.pdf https://stemcellsjournals.o Stem Cell Umbilical cord mesenchymal stem cells for COVID‐19 nlinelibrary.wiley.com/doi/ Jan‐21 Transplantation acuterespiratory distress syndrome: A double‐blind, RCT USA Lanzoni et al. NCT04355728 mesenchymal stem cell Safety of MSC in COVID‐19 patients epdf/10.1002/sctm.20‐ Medicine phase 1/2a,randomized controlled trial 0472 https://www.medrxiv.org/c Evaluation of a SARS‐CoV‐2 Vaccine NVX‐CoV2373 in Evaluation of a SARS‐CoV‐2 Vaccine NVX‐ 1‐Mar‐21 MedRxiv RCT USA Neil Formica et al ontent/10.1101/2021.02.26 NCT04368988 NVX‐CoV2373 vaccine Younger and Older Adults CoV2373 .21252482v1.full.pdf https://www.ncbi.nlm.nih.g Archives of Efficacy of favipiravir in COVID‐19 treatment: a ov/pmc/articles/PMC78296 chloroquine and 25‐Jan‐21 RCT Egypt Dabbous HM et al NCT04351295 To evaluate the efficacy of favipiravir Virology multi‐center randomized study 45/pdf/705_2021_Article_4 favipiravir 956.pdf https://www.nejm.org/doi/ NCT04381936; To evaluate the effects of potential Horby P et al 25‐Feb‐21 NEJM Dexamethasone in Hospitalized Patients with Covid‐19 RCT UK pdf/10.1056/NEJMoa20214 ISRCTN number, dexamethasone treatments in patients hospitalized with (RECOVERY Group) 36?articleTools=true 50189673 Covid‐19 at

https://www.nejm.org/doi/ To assess the efficacy and safety of Tocilizumab in Hospitalized Patients with Severe Covid‐ 25‐Feb‐21 NEJM RCT USA Rosas IO et al pdf/10.1056/NEJMoa20287 NCT04320615 tocilizumab tocilizumab in hospitalized patients with 19 Pneumonia 00?articleTools=true severe Covid‐19 pneumonia REMAP‐CAP https://www.nejm.org/doi/ To assess the efficacy of interleukin‐6 Interleukin‐6 Receptor Antagonists in Critically Ill ClinicalTrials.gov tocilizumab and 25‐Feb‐21 NEJM RCT UK Gordon AC et al pdf/10.1056/NEJMoa21004 receptor antagonists in critically ill Patients with Covid‐19 number, sarilumab 33?articleTools=true patients with Covid‐19 NCT02735707 Effect of tocilizumab on clinical outcomes at 15 days in Does tocilizumab improves clinical https://www.bmj.com/c 20‐Jan‐21 BMJ patients with severe or critical coronavirus disease RCT Brazil Veiga, V.C. et al. NCT04403685 tocilizumab outcomes for patients with severe or ontent/372/bmj.n84 2019: randomised controlled tria COVID‐19?. Interim Results of a Interim Results of a Phase 1–2a Trial of Ad26.COV2.S vaccine Phase Phase 1–2a Trial of NCT04436276. The safety and immunogenicity profiles 13‐Jan‐21 NEJM USA Sadoff J., et al. Ad26.COV2.S vaccine Covid‐19 Vaccine I/IIa Ad26.COV2.S Covid‐19 opens in new tab. of Ad26.COV2 Vaccine | NEJM To assess whether convalescent plasma https://www.medrxiv.or with high antibody levels expanded rather than low antibody levels is Early Safety Indicators of COVID‐19 Convalescent g/content/10.1101/2020 13‐Jan‐21 NEJM access USA Joyner et al. NCT04338360 Convalescent plasma associated with a lower risk of Plasma in 5,000 Patients .05.12.20099879v1.full.p program death. df Primary outcome: death within 30 days after plasma transfusion. https://pmj.bmj.com/co Short term, high‐dose vitamin D supplementation for Do high doses of cholecalciferol lead to Postgraduate ntent/early/2020/11/12/ 11‐Nov‐20 COVID‐19 disease: a randomised, placebo‐controlled, RCT India Rastogi et al. NCT04459247 Vitamin D SARS‐CoV‐2 negativity in greater Medical Journal postgradmedj‐2020‐ study (SHADE study) proportions? 139065 https://www.thelancet.c Safety and immunogenicity of S‐Trimer (SCB‐2019), a om/journals/lancet/artic protein subunit vaccine candidate for COVID‐19 in Phase I Dose‐finding and adjuvant justification 29‐Jan‐21 The Lancet Multinational Richmond et al. le/PIIS0140‐ NCT04405908 S‐Trimer (SCB‐2019) healthy adults: a phase 1, randomised, double‐blind, vaccine trial of SCB‐2019 vaccine placebo‐controlled trial 6736(21)00241‐ 5/fulltext https://www.thelancet.c Safety and efficacy of an rAd26 and rAd5 vector‐based om/journals/lancet/artic heterologous prime‐boost COVID‐19 vaccine: an Phase III Gam‐COVID‐Vac (Sputnik 02‐Feb‐21 The Lancet Russia Logunov et al. le/PIIS0140‐ NCT04530396 Efficacy and safety of Gam‐COVID‐Vac interim analysis of a randomised controlled phase 3 vaccine trial V) trial in Russia 6736(21)00234‐ 8/fulltext Early High‐Titer Plasma Early High‐Titer Plasma Does convalescent plasma reduce the Therapy to Prevent 06‐Jan‐21 NEJM Therapy to Prevent Severe RCT Argentina Libster R, et al. NCT04479163 Convalescent plasma development of severe respiratory Severe Covid‐19 in Older Covid‐19 in Older Adults disease? Adults | NEJM https://www.nejm.org/d Efficacy, Safety, and Immunogenicity of Efficacy and Safety of the mRNA‐1273 SARS‐CoV‐2 Vaccine ‐ oi/full/10.1056/NEJMoa mRNA‐1273 SARS‐CoV‐2 30‐Dec‐21 NEJM USA Baden LR, et al. NCT04470427 mRNA‐1273 Vaccine in Adults Aged 18 Vaccine phase III 2035389?query=feature Vaccine Years and Older to Prevent COVID‐19 d_coronavirus Enisamium is an inhibitor of the SARS‐CoV‐2 RNA https://www.medrxiv.or polymerase and shows improvement of recovery in g/content/10.1101/2021 Efficacy and safety of enisamium at 12‐Jan‐21 MedRxiv RCT Multinational Holubovska et al. NCT04682873 enisamium COVID‐19 patients in an interim analysis of a clinical .01.05.21249237v1.full‐ COVID‐19 patients trial text Safety and immunogenicity of SARS‐CoV‐2 https://www.medrxiv.or recombinant protein vaccine formulations in healthy Vaccine trial Safety and imunogenicity of CoV2 preS 20‐Jan‐21 MedRxiv Multinational Goepfert et al. g/content/10.1101/2021 NCT04537208 CoV2 preS dTM vaccine adults: a randomised, placebo‐controlled, dose‐ranging phase I/II dTM vaccine study .01.19.20248611v1 https://link.springer.com Annals of Pilot trial of high‐dose vitamin C in critically ill COVID‐ 09‐Jan‐21 RCT China Zhang et al. /article/10.1186/s13613‐ NCT04264533 Vitamin C Effect of high doses of vitamin C Intensive Care 19 patients 020‐00792‐3 International Efficacy and safety of favipiravir, an oral RNA‐ https://www.sciencedire Journal of dependent RNA polymerase inhibitor, in mild‐to‐ ct.com/science/article/pi CTRI/2020/05/0251 Efficacy and safety of favipiravir in 01‐Feb‐21 RCT India Udwadia et al. favipiravir Infectious moderate COVID‐19: A randomized, comparative, open‐ i/S120197122032453X?v 14 adults with mild‐to‐moderate COVID‐19 Diseases label, multicenter, phase 3 clinical trial ia%3Dihub https://www.thelancet.c Safety and efficacy of the ChAdOx1 nCoV‐19 vaccine om/journals/lancet/artic ISRCTN89951424, (AZD1222) against SARS‐CoV‐2: an interim analysis of phase I/II/III NCT04324606, ChAdOx1 nCoV‐19 To test the safety and efficacy of the 08‐Dec‐20 Lancet Multinational Voysey et al. le/PIIS0140‐ four randomised controlled trials in Brazil, South vaccine trial NCT04400838, and vaccine ChAdOx1 nCoV‐19 vaccine Africa, and the UK 6736(20)32661‐ NCT04444674 1/fulltext Baricitinib plus Effect of Baricitinib plus Remdesivir for Hospitalized Adults with Remdesivir for Baricitinib plus baricitinib (≤14 days) plus remdesivir 11‐Dec‐20 NEJM RCT USA Kalil A.C., et al NCT04401579 Covid‐19 Hospitalized Adults with Remdesivir (≤10 days) vs. remdesivir alone Covid‐19 | NEJM in hospitalized adults with Covid‐19 https://www.nejm.org/d To test the safety and efficacy of Tocilizumab in Patients Hospitalized with Covid‐19 17‐Dec‐20 NEJM RCT USA Salama et al. oi/10.1056/NEJMoa2030 NCT04372186 tocilizumab tocilizumab in hospitalized patients with Pneumonia 340 Covid‐19 pneumonia https://assets.researchs Exogenous Surfactant Versus Placebo in the Treatment quare.com/files/rs‐ IRCT2009120100280 Is surfactant effective in COVID‐19 31‐Dec‐20 Preprint of Moderate and Severe ARDS in COVID19: The Pilot RCT Iran Ghahremani et al. 136365/v1/adcad24b‐ surfactant 4N12 paients? Study of a Clinical Trial f7ed‐477b‐a235‐ 235f84f8ce1b.pdf WHO mortality trial of four repurposed Repurposed Antiviral remdesivir, antiviral drugs — remdesivir, Repurposed Antiviral Drugs for Covid‐19 — Interim WHO Soidarity Trial Drugs for Covid‐19 — hydroxychloroquine 02‐Dec‐20 NEJM RCT Multinational NCT04315948 hydroxychloroquine (HCQ), lopinavir, WHO Solidarity Trial Results Consortium Interim WHO Solidarity (HCQ), lopinavir, and and interferon beta‐1a (IFN)— in interferon beta‐1a (IFN) Trial Results | NEJM patients hospitalized with Covid‐19. Durability of Responses mRNA 1273 vaccine immunogenicity 3 Durability of Responses Phase I after SARS‐CoV‐2 mRNA‐ months after second 03‐Dec‐20 NEJM USA Widge A.T., et al. NCT04283461 mRNA 1273 vaccine after SARS‐CoV‐2 mRNA1273 Vaccination vaccine trial 1273 Vaccination | vaccination NEJM Safety and immunogenicity of INO‐4800 DNA vaccine https://www.sciencedire EClinicalMedici Phase I Safety and immunogenicity of INO‐4800 24‐Dec‐20 against SARS‐CoV‐2: A preliminary report of an open‐ USA/UK Tebas et al. ct.com/science/article/pi NCT04336410 INO‐4800 DNA vaccine ne vaccine trial vaccine label, Phase 1 clinical trial i/S2589537020304338

Phase 1/2 trial of SARSCoV‐2 vaccine ChAdOx1 nCoV‐ https://www.nature.co Safety and exploratory humoral and Phase I/II ChAdOx1 nCoV‐19 17‐Dec‐20 Nature Med. 19 with a booster dose induces multifunctional UK Barrett J.R., et al. m/articles/s41591‐020‐ NCT04400838 cellular immunogenicity of the AZD1222 vaccine trial vaccine AZD1222 antibody responses 01179‐4 vaccine REGN‐COV2, a Interim study results: effects of high REGN‐COV2, a Neutralizing viral loads with complications Neutralizing Antibody REGN‐COV2 antibody 17‐Dec‐20 NEJM Antibody Cocktail, in RCT USA Weinreich D.M NCT04425629 and death from coronavirus disease Cocktail, in Outpatients cocktail Outpatients with Covid‐19 2019 (Covid‐19)‐REGN‐COV2 with Covid‐19 | NEJM effects on outpatients Safety and immunogenicity clinical trial of an inactivated SARS‐CoV‐2 vaccine, BBV152 (a phase 2, https://www.medrxiv.or To test the immunogenicity and safety Phase I/II inactivated SARS‐CoV‐2 22‐Dec‐20 preprint ‐ BMJ double‐blind, randomised controlled trial) and the India Raches et al. g/content/10.1101/2020 NCT04471519 of BBV152: 3 µg and 6 µg with Algel‐ vaccine trial vaccine, BBV152 persistence of immune responses from a phase 1 .12.21.20248643v1 IMDG. follow‐up report A Neutralizing To test the effect of this antibody in A Neutralizing Monoclonal Antibody for Hospitalized ACTIV‐3/TICO LY‐ Monoclonal Antibody 22‐Dec‐20 NEJM RCT Denmark NCT04501978 LY‐CoV555 patients who are hospitalized with Covid‐ Patients with Covid‐19 CoV555 Study Group for Hospitalized Patients 19. with Covid‐19 | NEJM To test the effect of Tocilizumab on Efficacy of Tocilizumab in Efficacy of Tocilizumab multi‐organ dysfunction in a phase 3 10‐Dec‐20 NEJM Patients Hospitalized with RCT USA Stone J.H., et al in Patients Hospitalized NCT04356937 tocilizumab randomized controlled trial among Covid‐19 with Covid‐19 | NEJM hospitalized patients with COVID‐19 infection. https://bmcinfectdis.bio Effect of Arbidol (Umifenovir) on COVID‐19: a medcentral.com/articles IRCT2018072504059 To determine the effect of Arbidol (ARB) 14‐Dec‐20 BMC Infect Dis RCT Iran Marzieh et al. Arbidol (Umifenovir) randomized controlled trial. /10.1186/s12879‐020‐ 6N2 on COVID‐19 disease. 05698‐w https://trialsjournal.bio Interferon ß‐1a (IFNß‐1a) in COVID‐19 patients EudraCT 2020‐ To test the efficacy of Interferon‐β‐1a medcentral.com/articles 23‐Dec‐20 Trials (INTERCOP): study protocol for a randomized RCT Italy Bosi et al. 002458‐25, Interferon ß‐1a (IFNß‐1a) (IFNβ‐1a), in COVID‐19 patients in an /10.1186/s13063‐020‐ controlled trial. NCT04449380 open label, randomized clinical trial. 04864‐4 To evaluate the efficacy and safety of BNT162b2 is a lipid Safety and Efficacy of nanoparticle–formulated, nucleoside‐ Safety and Efficacy of the BNT162b2 mRNA Covid‐19 phase II NCT04368728. 10‐Dec‐20 NEJM USA Polack F.P., et al. the BNT162b2 mRNA BNT162b2 vaccine modified RNA vaccine that encodes a Vaccine vaccine trial opens in new tab Covid‐19 Vaccine | NEJM prefusion stabilized, membraneanchored SARS‐CoV‐2 fulllength spike protein. https://academic.oup.co Journal of Sofosbuvir and daclatasvir for the treatment of COVID‐ m/jac/advance‐ IRCT2020040304692 Is sofosbuvir/daclatasvir effective in 18‐Dec‐20 Antimicrobial 19 outpatients: a double‐blind, randomized controlled RCT Iran Roozbeh et al. article/doi/10.1093/jac/ sofosbuvir, daclatasvir 6N1 COVID‐19 patiets? Chemotherapy trial dkaa501/6041772?login =true https://journals.lww.co m/ccejournal/Fulltext/2 Intravenous Immunoglobulin Plus Methylprednisolone To asses the efficacy and safety of IV 16 November Critical Care George Sakoulas, et 020/11000/Intravenous_ Mitigate Respiratory Morbidity in Coronavirus Disease RCT USA NCT04411667 Immunoglobulins immunoglobulin in hospitalized COVID‐ 2020 Explorations al. Immunoglobulin_Plus_ 2019 19 patients. Methylprednisolone.14. aspx To evaluate the effect of combining Biological Trace https://link.springer.com 23 November Do Zinc Supplements Enhance the Clinical Efficacy of Sherief Abd‐Elsalam, Zinc, chloroquine/hydroxychloroquine and Element RCT Egypt /article/10.1007/s12011‐ NCT04447534 2020 Hydroxychloroquine?: a Randomized, Multicenter Trial et al. Hydroxychloroquine zinc in the treatment of COVID‐19 Research 020‐02512‐1 patients. Effect of Vitamin D3 Supplementation vs Placebo on https://www.medrxiv.or To determine if vitamin D3 Hospital Length of Stay in Patients with Severe COVID‐ g/content/10.1101/2020 supplementation can reduce hospital 17‐Nov MedRxiv RCT Brazil Murai et al. NCT04449718 Vitamin D3 19: A Multicenter, Double‐blind, Randomized 3 .11.16.20232397v1.full.p length of stay in hospitalized patients Controlled Trial df with severe COVID‐19? To determine whether a single, 180 mcg https://www.medrxiv.or subcutaneous dose of Peginterferon Peginterferon Lambda‐1a for treatment of outpatients g/content/10.1101/2020 Peginterferon Lambda‐ Lambda‐1a (Lambda) could shorten the 23‐Nov MedRxiv with uncomplicated COVID‐19: a randomized placebo‐ RCT USA Jagannathan et al. NCT04331899 .11.18.20234161v1.full.p 1a duration of viral shedding or symptoms controlled trial df in patients with mild to moderate COVID‐ 19. https://www.medrxiv.or To evaluate the efficacy of convalescent plasma with high titers of SARS‐CoV2 Prevention of severe COVID‐19 in the elderly by early g/content/10.1101/2020 21‐Nov MedRxiv RCT Argentina Libster et al. NCT04479163 Convalescent plasma antibody administered within 72 hours hightiter plasma .11.20.20234013v1.full.p of mild symptoms to elderly patients df with Covid‐19 To estimate the efficacy and safety of A two‐arm, randomized, controlled, multi‐centric, open‐ https://www.medrxiv.or Itolizumab in the treatment of cytokine label Phase‐2 study to evaluate the efficacy and safety g/content/10.1101/2020 CTRI/2020/05/0249 release syndrome in patients with 02‐Dec MedRxiv RCT India Kumar et al. Itolizumab of Itolizumab in moderate to severe ARDS patients due .12.01.20239574v1.full.p 59 moderate to severe acute respiratory to COVID‐19 df distress syndrome (ARDS) due to COVID‐ 19. 5‐Alpha‐Reductase Inhibitors Reduce Remission Time https://www.medrxiv.or To determine if 5‐alpha‐reductase of COVID‐19: Results From a Randomized Double Blind g/content/10.1101/2020 inhibitors (5ARis) are a beneficial 18‐Nov MedRxiv RCT Brazil, USA Cadegiani et al. NCT04446429 Dutasteride Placebo Controlled Interventional Trial in 130 SARSCoV‐ .11.16.20232512v1.full.p treatment for COVID‐19 if given after 2 Positive Men df SARS‐CoV‐2 infection https://reader.elsevier.c om/reader/sd/pii/S1567 576920336766?token=E To test the effect Pentoxifylline (PTX) on International Pentoxifylline decreases serum LDH levels and parameters such as LDH, lymphocyte DD4B561C8D7F700793B 11‐Nov Immunopharma increases lymphocyte count in COVID‐19 patients: RCT Mexico Maldonado et al. COF‐002495 Pentoxifylline count, days of hospitalization, mortality, 55AFFA9EE8F0CD28010 cology Results from an external pilot study and the need for intubation on patients BE3E0CADC0EF90237E4 with severe and moderate COVID‐19 EF73330CF63D0FDA8F3 3F2F0AD9CA7536BD33F

https://www.nejm.org/d hydroxychloroquine, Repurposed Antiviral Drugs for Covid‐19 — Interim WHO Solidarity Trial ISRCTN83971151, N lopinavir/ritonavir, 02‐Dec‐20 NEJM RCT Multinational oi/10.1056/NEJMoa2023 effects of drugs on in‐hospital mortality WHO Solidarity Trial Results Consortium CT04315948 interferon beta1, 184 remdesivir https://www.nejm.org/d Does postexposure prophylaxis with A Cluster‐Randomized Trial of Hydroxychloroquine for 24‐Nov‐20 NEJM RCT Spain Mitjà et al. oi/10.1056/NEJMoa2021 NCT04304053 Hydroxychloroquine hydroxychloroquine prevent SARS‐CoV‐2 Prevention of Covid‐19 801 infection? https://www.nejm.org/d Is treatment with convalescent plasma A Randomized Trial of Convalescent Plasma in Covid‐ 24‐Nov‐20 NEJM RCT Argentina Simonovich et al. oi/10.1056/NEJMoa2031 NCT04383535 Convalescent plasma associated with improved clinical 19 Severe Pneumonia 304 outcomes in COVID‐19 patients? Safety and immunogenicity of ChAdOx1 nCoV‐19 https://www.sciencedire vaccine administered in a prime‐boost regimen in phase II/III ct.com/science/article/pi NCT04400838, Safety and immunogenicity of ChAdOx1 19‐Nov‐20 The Lancet UK Ramasamy et al. ChAdOx1 vaccine young and old adults (COV002): a single‐blind, vaccine trial i/S0140673620324661?v ISRCTN 15281137 vaccine in young and old adults randomised, controlled, phase 2/3 trial ia%3Dihub Safety, tolerability, and immunogenicity of an https://www.sciencedire Lancet Infect. inactivated SARS‐CoV‐2 vaccine in healthy adults aged I/II vaccine ct.com/science/article/pi Safety, tolerability and immunogenicity 18‐Nov‐20 China Zhang et al. NCT04352608 CoronaVac vaccine Dis. 18–59 years: a randomised, double‐blind, placebo‐ trial i/S1473309920308434?v of CoronaVac vaccine controlled, phase 1/2 clinical trial. ia%3Dihub https://www.medrxiv.or Randomized controlled trial of convalescent plasma Pilot study designed to inform the g/content/10.1101/2020 04‐Nov MedRxiv therapy against standard therapy in 2 patients with RCT Bahrain, Ireland Al Qahtani et al. NCT04356534 Convalescent plasma design of a definitive phase 3 clinical .11.02.20224303v1.full.p severe COVID‐19 disease trial. df https://www.medrxiv.or To evaluate a single subcutaneous Peginterferon‐lambda for the treatment of COVID‐19 in g/content/10.1101/2020 12/11/2020 MedRxiv RCT Canada Feld et al. NCT04354259 Peginterferon injection of peginterferon‐lambda in outpatients .11.09.20228098v1.full.p outpatients with COVID‐19. df https://reader.elsevier.c om/reader/sd/pii/S1567 576920336729?token=1 International Evaluating the effects of Intravenous Immunoglobulin To investigate the potential usefulness 3C23CAB7F2F51222936F IRCT2015122702572 Intravenous 13‐Nov Immunopharma (IVIg) on the management of severe COVID‐19 cases: A RCT Iran Tabarsi et al. of IVIg for the management of severe 6967643ECEC50F680C6C 6N20 Immunoglobulin cology randomized controlled trial cases of Covid‐19. 1B600298B1211225F0DF EC4733E630469CDAF7A 7C229585B41FD1EE

To evaluate the therapeutic International Randomized Controlled Open Label Trial on the Use of https://www.sciencedire effectiveness of favipiravir combined 9 November 2020 Journal of Favipiravir Combined with Inhaled Interferon beta‐1b ct.com/science/article/pi Favipiravir, interferon RCT Oman Faryal Khamis, et al. NA with inhaled interferon beta‐1b in adult (preprint) Infectious in Hospitalized Patients with Moderate to Severe i/S1201971220323195?v beta‐1b patients hospitalized with moderate to Diseases COVID‐19 Pneumonia ia%3Dihub severe COVID‐19 pneumonia. https://academic.oup.co Clinical Randomized, double‐blinded and placebo‐controlled Phase 2 m/cid/advance‐ Assess the safety and immunogenitcity Preprint Infectious phase II trial of an inactivated SARS‐CoV‐2 vaccine in China Yanchun Che, et al. NCT04412538 Inactivated vaccine vaccine trial article/doi/10.1093/cid/ of this inactiviated vaccine Diseases healthy adults ciaa1703/5962856 To evaluate the efficacy of PEP with HCQ International https://www.sciencedire Post‐exposure prophylaxis with hydroxychloroquine for the prevention of COVID‐19 in 6 November 2020 Journal of Deba Prasad Dhibar, ct.com/science/article/pi for the prevention of COVID‐19, a myth or a reality? RCT India NCT04408456 Hydroxychloroquine asymptomatic non‐HCW in‐ dividuals (in press) Antimicrobial et al. i/S0924857920304350?v The PEP‐CQ Study who were at risk for SARS‐CoV‐2 Agents ia%3Dihub infection To assess the safety, tolerability, and Phase 1 trial of a Candidate Recombinant Virus‐Like https://www.medrxiv.or immunogenicity of CoVLP at three dose Phase 1 Preprint MedRxiv Particle Vaccine for Covid‐19 Disease Produced in Canada Brian J Ward, et al. g/content/10.1101/2020 NCT04450004 CoVLP vaccine levels unadjuvanted or adjuvanted with vaccine Trial Plants .11.04.20226282v1 either CpG 1018 or AS03 in healthy adults 18 to 55 years of age. https://www.sciencedire E‐Clinical An open‐label, randomized trial of the combination of To evaluate the efficacy and safety in ct.com/science/article/pi 27 October 2020 Medicine IFN‐κ plus TFF2 with standard care in the treatment of RCT China Weihui Fu, et al. ChiCTR2000030262 IFN‐κ plus TFF2 patients with moderate COVID‐19 f the i/S2589537020302911?v (Lancet) patients with moderate COVID‐19 combination of IFN‐κ plus TFF2 ia%3Dihub https://www.thelancet.c Safety and efficacy of inhaled nebulised interferon beta‐ The Lancet om/journals/lanres/artic 1a (SNG001) for treatment of SARS‐CoV‐2 infection: a 2020‐001023‐14, Efficacy and safety of inhaled nebulised 12‐Nov‐20 Respiratory RCT UK Monk et al. le/PIIS2213‐ INF‐beta 1a randomised, double‐blind, placebo‐controlled, phase 2 NCT04385095 interferon beta‐1a Medicine trial 2600(20)30511‐ 7/fulltext Determine whether fluvoxamine, given Fluvoxamine vs Placebo and Clinical Deterioration in https://jamanetwork.co during mild COVID‐19 illness, prevents 12‐Nov‐20 JAMA Outpatients With Symptomatic COVID‐19A RCT USA Lenze et al. m/journals/jama/article‐ NCT04342663 Fluvoxamine clinical deterioration and decreases the Randomized Clinical Trial abstract/2773108 severity of disease Antiviral effect of high‐dose ivermectin in adults with https://papers.ssrn.com Preprint The Lancet COVID‐19: a pilot randomised, controlled, open label, RCT Argentina Krolewiecki et al. /sol3/papers.cfm?abstra NCT004381884 Ivermectin Does ivermectin reduce the viral load? multicentre trial ct_id=3714649 https://www.medrxiv.or To compare the efficacy and safety of Efficacy of Convalescent Plasma Therapy compared to g/content/10.1101/2020 convalescent plasma with fresh frozen 27‐Oct MedRxiv Fresh Frozen Plasma in Severely ill COVID‐19 Patients: RCT India Bajpai et al. NCT04346446 Convalescent plasma .10.25.20219337v1.full.p plasma (FFP) in severe COVID‐19 A Pilot Randomized Controlled Trial. df patients https://www.medrxiv.or To evaluate the efficacy and safety of A placebo‐controlled double blind trial of Dubée et al. for the g/content/10.1101/2020 hydroxychloroquine in adult patients 21‐Oct MedRxiv RCT France NCT04325893 Hydroxychloroquine hydroxychloroquine in mild‐to‐moderate COVID‐19 HYCOVID study group .10.19.20214940v1.full.p with mild‐to‐moderate COVID‐19 at risk df of worsening. https://www.medrxiv.or To evaluate whether early nitazoxanide Early use of nitazoxanide in mild Covid‐19 disease: g/content/10.1101/2020 therapy would be effective in 23‐Oct MedRxiv RCT Brazil Rocco et al. NCT04552483 Nitazoxanide randomized, placebo controlled trial .10.21.20217208v1.full.p accelerating symptom resolution in df patients with mild COVID‐19. https://www.medrxiv.or To test the combinational therapy of Controlled randomized clinical trial on using Ivermectin g/content/10.1101/2020 Ivermectin and Doxycycline in treating 27‐Oct MedRxiv with Doxycycline for treating COVID‐19 patients in RCT Iraq Hashim et al. NCT04591600 Ivermectin + Doxycycline .10.26.20219345v1.full.p COVID‐19 patients at different stages of Baghdad, Iraq df the disease. Treatment with human umbilical cord‐derived https://www.medrxiv.or To assess the efficacy and safety of human umbilical cord‐ mesenchymal stem cells for COVID‐19 patients with g/content/10.1101/2020 human umbilical cord‐mesenchymal 21‐Oct MedRxiv RCT China Shi et el. NCT04288102 derived mesenchymal lung damage: a randomised, double‐blind, placebo‐ .10.15.20213553v2.full.p stem cells (UC‐MSCs) to treat severe stem cells controlled phase 2 trial df COVID‐19 patients with lung damage. Umbilical Cord Mesenchymal Stem Cells for COVID‐19 https://papers.ssrn.com human umbilical cord‐ To determine safety and explore efficacy 26‐Oct Lancet pre‐print ARDS: A Double Blind, Phase 1/2a, Randomized RCT USA Lanzoni et al. /sol3/papers.cfm?abstra NCT04355728 derived mesenchymal of Umbilical Cord (UC)‐MSC infusions in Controlled Trial ct_id=3696875 stem cells COVID‐19 ARDS. https://academic.oup.co To determine whether J Antimicrob Sofosbuvir/daclatasvir regimens for the treatment of m/jac/advance‐ sofosbuvir/daclatasvir‐based regimens 01‐Nov Meta‐analysis UK/Iran Simmons et al. N/A sofosbuvir/daclatasvir Chemother COVID‐19: an individual patient data meta‐analysis article/doi/10.1093/jac/ improve clinical outcomes of patients dkaa418/5924537 with moderate or severe COVID‐19. https://papers.ssrn.com To evaluate the efficacy and safety of Phase 3 Trial of Coronavir (Favipiravir) in Patients with 26‐Oct Lancet pre‐print RCT Russia Ruzhentsova et al. /sol3/papers.cfm?abstra NCT04501783 Favipiravir favipiravir for treatment of mild to Mild to Moderate COVID‐19 ct_id=3696907 moderate COVID‐19 https://www.sciencedire Imunopatholog Treatment of Coronavirus Disease 2019 Patients with Efficacy of COVID‐19 convalescent ct.com/science/article/pi 01‐Nov‐20 y and infectious Convalescent Plasma Reveals a Signal of Significantly RCT USA Salazar et al. Convalescent plasma plasma transfusion for severe and/or i/S0002944020303709?v diseases Decreased Mortality critical COVID‐19. ia%3Dihub https://www.nejm.org/d Efficacy of Tocilizumab in Patients Hospitalized with Does tocilizumab prevent intubation or 21‐Oct‐20 NEJM RCT USA Stone et al. oi/pdf/10.1056/NEJMoa NCT04356937 Tocilizumab Covid‐19 death? 2028836 https://jamanetwork.co To determine whether tocilizumab (TCZ) Effect of Tocilizumab vs Usual Care in Adults JAMA Internal m/journals/jamainternal improves outcomes of patients 20‐Oct‐20 Hospitalized With COVID‐19 and Moderate or Severe RCT France Hermine et al. NCT04331808 Tocilizumab Medicine medicine/fullarticle/277 hospitalized with moderate‐to‐severe Pneumonia: A Randomized Clinical Trial 2187 COVID‐19 pneumonia https://jamanetwork.co Effect of Tocilizumab vs Standard Care on Clinical NCT04346355; JAMA Internal m/journals/jamainternal To evaluate the effect of early 20‐Oct‐20 Worsening in Patients Hospitalized With COVID‐19 RCT Italy Salvarani et al. EudraCT Identifier: Tocilizumab Medicine medicine/fullarticle/277 tocilizumab administration PneumoniaA Randomized Clinical Trial 2020‐001386‐37. 2186 International Journal of https://pharmascope.or Efficacy of umifenovir in the treatment of mild and Randomized To evaluate the efficacy of umifenovir in 01‐Oct‐20 Research in Kyrgizstan Yethindra et al. g/ijrps/article/view/2839 NA Umifenovir moderate covid‐19 patients clinical study mild and moderate COVID‐19 patients Pharmaceutical /6116 Sciences https://www.nejm.org/d To evaluate the efficacy of remdesivir in Remdesivir for the Treatment of Covid‐19 — Final 8 October 2020 NEJM RCT USA John H. Beigel, et al. oi/10.1056/NEJMoa2007 NCT04280705 Remdesivir shortening time to recovery in Repor 764 hospitalized COVID‐19 patients. https://www.sciencedire Safety and immunogenicity of an inactivated SARS‐CoV‐ To assess the safety and Phase 1/2 ct.com/science/article/pi 15 October 2020 Lancet 2 vaccine, BBIBP‐CorV: a randomised, double‐blind, China Shengli Xia, et al. ChiCTR2000032459. BBIBP‐CorV immunogenicity of an inactivated SARS vaccine trial i/S1473309920308318?v placebo‐controlled, phase 1/2 trial CoV2 vaccine ia%3Dihub https://www.medrxiv.or Lopinavir/ritonavir, Repurposed antiviral drugs for COVID‐19 remdesivir, Are repurposed andiviral drugs effective 15 October 2020 MedRiXV RCT International Hongchao Pan, et al. g/content/10.1101/2020 ISRCTN83971151 –interim WHO SOLIDARITY trial results hydroxychloroquine, in treating COV ID19? .10.15.20209817v1 interferon To assess the safety and dose response https://www.nejm.org/d through reduction of viral load of SARS‐CoV‐2 Neutralizing Antibody LY‐CoV555 in Monoclonal antibody, LY‐ 28 October 2020 NEJM Phase 2 RCT USA Peter Chen, et al. oi/10.1056/NEJMoa2029 NCT04427501 monoclonal antibody LY‐CoV555 in Outpatients with Covid‐19 CoV555 849 patients with mild or moderate COVID‐ 19 To assess if a simple incentive to self‐ https://papers.ssrn.com prone for a maximum of 12 h per day Self‐Proning in COVID‐19 Patients on Low‐Flow Oxygen would decrease oxygen needs in 21 October 2020 Lancet preprint RCT Switzerland Aileen Kharat, et al. /sol3/papers.cfm?abstra SNCTP000003718 Self‐proning Therapy: A Cluster Randomised Controlled Trial patients admitted for COVID‐19 ct_id=3692538 pneumonia on low‐flow oxygen therapy. International Interim analysis of an open‐label randomized https://onlinelibrary.wil To assess if nasal irrigation can reduce 11 September Forum of controlled trial evaluating nasal irrigations in RCT USA Kyle S. Kimura, et al. ey.com/doi/10.1002/alr. NA Nasal irrigations symptoms and viral shedding in mild 2020 Allergy and non‐hospitalized patients with coronavirus disease and moderate COVID‐19 patients Rhinology 2019 22703 https://www.medrxiv.or To assess the safety and efficacy of Tocilizumab in nonventilated patients hospitalized with tocilizumab in patients hospitalized and Preprint MedRiXV RCT USA Carlos Salama, et al. g/content/10.1101/2020 NCT04372186 Tocilizumab Covid‐19 pneumonia non‐ventilated with Covid‐19 .10.21.20210203v1 pneumonia. The use of intravenous immunoglobulin gamma for the https://bmcinfectdis.bio To evaluate the efficacy of intravenous BMC Infectious treatment of severe coronavirus disease 2019: a Naser Gharebaghi, et medcentral.com/articles IRCT2020050104725 21 October 2020 RCT Iran Immunoglobulin gamma immunoglobulin (IVIg) in patients with Diseases randomized placebo‐controlled double‐blind clinical al. /10.1186/s12879‐020‐ 9N1 severe COVID‐19 infection. trial 05507‐4

Anti‐C5a antibody IFX‐1 (vilobelimab) treatment versus https://www.thelancet.c Phase 2 study to explore the potential 28 September best supportive care for patients with severe COVID‐19 Alexander P J Vlaar, et om/action/showPdf?pii= Lancet RCT Netherlands NCT04333420 Vilobelimab benefit and safety of IFX‐1 (vilobelimab) 2020 (PANAMO): an exploratory, open‐label, phase 2 al. S2665‐ in patients with severe COVID‐19. randomised controlled trial 9913%2820%2930341‐6

https://www.nejm.org/d Is the SARS CoV‐2 mRNA 1273 safe and 29 September Safety and Immunogenicity of SARS‐CoV‐2 mRNA‐1273 Vaccine trial Evan J. Anderson, et NEJM USA oi/full/10.1056/NEJMoa NCT04283461 mRNA‐1273 vaccine well tolerated in older adults and does it 2020 Vaccine in Older Adults Phase 1 al. 2028436 ellicit an immune response? 30 September https://www.nature.co Does the BNT162b1 vaccine elicit both COVID‐19 vaccine BNT162b1 elicits human antibody Vaccine trial 2020 ‐pre‐ Nature Germany Ugur Sahin, et al. m/articles/s41586‐020‐ NCT04380701 BNT162b1 vaccine antibody and T‐cell response in healthy and TH1 T‐cell responses Phase 1 and 2 approved 2814‐7 adults? https://assets.researchs To evaluate the efficacy and safety of quare.com/files/rs‐ recombinant super‐compound Research Engineered interferon alpha effectively improves Engineered interferon Preprint RCT China Chuan Li, et al. 65224/v1/22886bf0‐ ChiCTR2000029638 interferon versus traditional interferon Square clinical outcomes of COVID‐19 patients alpha ce06‐4d42‐aeb6‐ alpha in patients with moderate to c73ebb7c2003.pdf severe COVID‐19 https://www.sciencedire International To evaluate the efficacy and safety of Interferonβ‐1b in treatment of severe COVID‐19: A ct.com/science/article/pi IRCT2010022800344 24 August 2020 Immunopharma RCT Iran Hamid Rahmani, et al. Interferon β‐1b interferon (IFN) β‐1b in the treatment of randomized clinical trial i/S1567576920323304?v 9N27 cology patients with severe COVID‐19 ia%3Dihub To evaluate the efficacy of https://jamanetwork.co hydroxychloroquine to prevent Efficacy and Safety of Hydroxychloroquine vs Placebo 30 September Benjamin S Abella, et m/journals/jamainternal transmission of SARS‐CoV‐2 in hospital‐ JAMA for Pre‐exposure SARS‐CoV‐2 Prophylaxis Among RCT USA NCT04329923 Hydroxychloroquine 2020 al. medicine/fullarticle/277 based HCWs with exposure to patients Health Care Workers 1265 with COVID‐19 using a pre‐exposure prophylaxis strategy Drug treatments for covid‐19: living systematic review To compare the effects of treatments 4 September Systematic International Reed AC Siemieniuk, https://www.bmj.com/c BMJ and NA All treatments for coronavirus 2020 review collaboration et al. ontent/370/bmj.m2980 network meta‐analysis disease 2019 (covid‐19). To compare the rate of clinical https://www.ncbi.nlm.ni improvement among patients with Effect of remdesivir on patients with COVID‐19: A 15‐Oct Virus Research Meta‐analysis USA, Japan Yokoyama et al. h.gov/pmc/articles/PMC N/A Remdesivir COVID‐19 who received 5‐day course of network meta‐analysis of randomized control trials 7437510/pdf/main.pdf remdesivir versus 10‐day course of remdesivir versus standard care.

To investigate the safety and https://www.medrxiv.or immunogenicity of an inactivated viral An in‐depth investigation of the safety and g/content/10.1101/2020 vaccine in immunized individuals in a 06‐Sep MedRxiv immunogenicity of an inactivated 2 SARS‐CoV‐2 Phase 1 RCT China Pu et el. NCT04412538 Vaccine .09.27.20189548v1.full.p phase I trial, especially focusing on vaccine df safety with regard to the immunopathology of the vaccine. https://www.medrxiv.or Clearing the fog: Is Hydroxychloroquine effective in To assess the efficacy of HCQ in Mehmood Kamran et g/content/10.1101/2020 11‐Oct MedRxiv reducing Corona virus disease‐2019 progression: A RCT Pakistan NCT04491994 Hydroxychloroquine reducing disease progression in mild al. .07.30.20165365v2.full.p randomized controlled trial COVID‐19 df https://www.thelancet.c Lopinavir–ritonavir in patients admitted to hospital Whether lopinavir–ritonavir improves Horby et al. om/action/showPdf?pii= ISRCTN 50189673, 05‐Oct‐20 The Lancet with COVID‐19 (RECOVERY): a randomised, controlled, RCT UK lopinavir/ritonavir outcomes in patients admitted to (RECOVERY GROUP) S0140‐ NCT04381936 open‐label, platform trial hospital with COVID‐19 6736%2820%2932013‐4 https://www.sciencedire An open‐label, randomized trial of the combination of EClinicalMedici ct.com/science/article/pi Efficacy and safety of IFN‐κ and TFF2 in 20‐Sep‐20 IFN‐kappa plus TFF2 with standard care in the RCT China Fu et al. ChiCTR2000030262 IFN‐κ , TFF2 ne i/S2589537020302911?v COVID patients. treatment of patients with moderate COVID‐19 ia%3Dihub Vaccine: non‐replicating https://www.medrxiv.or adenovirus 26 based Safety and immunogenicity of the Ad26.COV2.S COVID‐ Phase 1/2a Netherlands, Belgium, g/content/10.1101/2020 vector expressing the To evaluate the efficacy of a single 25‐Sep MedRxiv 19 vaccine candidate: interim results of a phase 1/2a, Sadoff et al. NCT04436276 RCT USA .09.23.20199604v1.full.p stabilized pre‐fusion vaccination of 5x1010 vp of Ad26.COV2.S double‐blind, randomized, placebo‐controlled trial df spike protein of SARS‐ CoV‐2

https://www.medrxiv.or To determine the effectiveness of Hydroxychloroquine as pre‐exposure prophylaxis for g/content/10.1101/2020 hydroxychloroquine as pre‐exposure 21‐Sep MedRxiv RCT USA Rajasingham et al. NCT04328467 Hydroxychloroquine COVID‐19 in healthcare workers: a randomized trial .09.18.20197327v1.full.p prophylaxis in healthcare workers at df high‐risk of SARS‐CoV‐2 exposure Treatment with an Anti‐CK2 Synthetic Peptide https://www.medrxiv.or IG/CIGB300I/CV/200 To explore safety and efficacy of CIGB‐ Improves Clinical 3 Response in Covid‐19 Patients with g/content/10.1101/2020 Anti‐CK2 Synthetic 22‐Sep MedRxiv RCT Cuba Cruz et al. 1, ATENEA‐Co‐300 325, an anti‐CK2 peptide, in COVID‐19 Pneumonia. A Randomized and 4 Controlled Clinical .09.03.20187112v2.full.p Peptide, CIGB‐325 trial patients. Trial df

https://www.sciencedire To compare the rate of clinical improvement among patients with Effect of remdesivir on patients with COVID‐19: A ct.com/science/article/pi 15‐Oct Virus Research Meta‐analysis USA, Japan Yujiro Yokoyama et al. N/A Remdesivir COVID‐19 who received 5‐day course of network meta‐analysis of randomized control trials i/S0168170220310443?v remdesivir versus 10‐day course of ia%3Dihub remdesivir versus standard care. https://academic.oup.co Clinical Remdesivir for Severe COVID‐19 versus a Cohort Susan A. Olender, et m/cid/advance‐ NCT04292899 and Efficacy of remdesivir in COVID19 24 July 2020 Infectious RCT vs cohort USA Remdesivir Receiving Standard of Care al. article/doi/10.1093/cid/ EUPAS34303 patients Diseases ciaa1041/5876045 Assess the efficacy of favipiravir in Antimicrobial A prospective, randomized, open‐label trial of early https://aac.asm.org/con 17 November asymptomatic or mild COVID19 patients Agents versus late favipiravir in hospitalized patients with RCT Japan Yohei Doi, et al. tent/early/2020/09/16/ jRCTs041190120 Favipiravir 2020 in viral clearance, and resolution of Chemotherapy COVID‐19 AAC.01897‐20 symptoms https://virologyj.biomed Favipiravir versus other antiviral or standard of care for Systematic To evaluate the efcacy and safety of the Dhan Bahadur central.com/articles/10. 24‐Sep Virology Journal COVID‐19 treatment: a rapid systematic review and review & Nepal N/A Favipiravir drug Favipiravir as a treatment for Shrestha et al. 1186/s12985‐020‐01412‐ meta‐analysis meta‐analysis COVID‐19. z

https://www.thrombosis To compare therapeutic enoxaparin Therapeutic versus prophylactic anticoagulation for 20 September Thrombosis Anna Cristina Bertoldi research.com/article/S0 Enoxaparin, treatment to standard prophylactic severe COVID‐19: A randomized phase II clinical trial RCT Brazil REBEC RBR‐949z6v 2020 Research Lemos, et al. 049‐3848(20)30530‐ anticoagulants anticoagulant treatment in severe (HESACOVID) 2/fulltext#%20 COVID19

https://academic.oup.co To evaluate the efficacy and safety of Clinical Treatment of COVID‐19 Patients with Prolonged Post‐ m/cid/advance‐ leflunomide to treat COVID‐19 patients Preprint Infectious Symptomatic Viral Shedding with Leflunomide ‐‐ a RCT China Wang, et al ChiCTR 2000030058 Leflunomide article/doi/10.1093/cid/ with prolonged post‐symptomatic viral Diseases Single‐Center, Randomized, Controlled Clinical Trial ciaa1417/5909448 shedding. https://www.clinicalmicr Effect of hydroxychloroquine with or without To assess the effect of chloroquine and Clinical Systematic obiologyandinfection.co Chloroquine, azithromycin on the mortality of coronavirus disease hydroxychloroquine with or without 26 August 2020 Microbiology Review and France, Switzerland Thibault Fiolet, et al. m/article/S1198‐ NA hydroxychloroquine, 2019 (COVID‐19) patients: a systematic review and azithromycin on the mortality of COVID‐ and Infection Meta‐analysis azithromycin meta‐analysis 743X(20)30505‐ 19 patients X/fulltext To evaluate and compare different Efficacy of commercial mouth‐rinses on SARS‐CoV‐2 https://www.medrxiv.or Chaminda Jayampath commercial moutwash solutions and Preprint MedRxIV viral load in saliva: Randomized Control Trial in RCT Singapore g/content/10.1101/2020 NA Mouth wash Seneviratne, et al. their effect on reducing salivary viral Singapore .09.14.20186494v1 load Early Anti‐SARS‐CoV‐2 Convalescent Plasma in Patients https://www.medrxiv.or Evaluate the safety and efficacy of María Elvira Balcells, Preprint MedRxIV Admitted for COVID‐19: A Randomized Phase II Clinical RCT Chile g/content/10.1101/2020 NCT04375098 Covalescent Plasma convalescent plasma and compare an et al. Trial .09.17.20196212v1 early vs deferred treatement strategy Evaluate the efficacy of bromhexine in Effect of bromhexine on clinical outcomes and https://bi.tbzmed.ac.ir/A IRCT2020031170467 intensive care unit (ICU) admission, 19 July 2020 Bioimpacts mortality in COVID‐19 patients: A randomized clinical RCT Iran Khalil Ansarin Bromhexine rticle/bi‐23240 97N4 mechanical ventilation, and mortality in trial patients with COVID‐19.

https://www.tandfonlin Expert Review Identify studies pertaining to antivirals The effect of antivirals on COVID‐19: a systematic Systematic e.com/doi/abs/10.1080/ 12‐Sep‐20 of Anti‐Infective Hussain et al. UK NA Antivirals in COVID‐19 patients and review the review review 14787210.2021.1823832 Therapy clinical outcomes ?journalCode=ierz20 https://academic.oup.co Clinical Double‐blind, randomized, placebo‐controlled trial To determine whether NAC in high 23 September Julio Cesar Garcia de m/cid/advance‐ Infectious with N‐acetylcysteine for treatment of severe acute RCT Brazil doses can avoid respiratory failure in 2020 Alencar, et al. article/doi/10.1093/cid/ Diseases respiratory syndrome caused by COVID‐19 patients with Covid‐19. ciaa1443/5910353 https://erj.ersjournals.co European Intravenous methylprednisolone pulse as a treatment m/content/early/2020/0 IRCT2020040404694 Is methylprednisolone effective in 17‐Sep‐20 Respiratory for hospitalised severe COVID‐19 patients: results from RCT Iran Edalatifard et al. Methylprednisolone 9/09/13993003.02808‐ 7N1 treatment of COVID‐19 patients? Journal a randomised controlled clinical trial 2020 https://journals.plos.org Interventions for treatment of COVID‐19: A living /plosmedicine/article?id Effects of all treatment interventions for 17‐Sep‐20 Plos Medicine systematic review with meta‐analyses and trial Meta‐analysis Denmark Juul et al. NA NA =10.1371/journal.pmed. COVID‐19 sequential analyses (The LIVING Project) 1003293 Safety and immunogenicity of an rAd26 and rAd5 https://www.sciencedire Safety and immunogenicity of two vector‐based heterologous prime‐boost COVID‐19 ct.com/science/article/pi NCT04436471 and 04‐Sep‐20 The Lancet CT Russia Logunov et al. vaccine formulations (frozen and lyophilised) of vaccine in two formulations: two open, non‐ i/S0140673620318663?v NCT04437875 vaccine randomised phase 1/2 studies from Russia ia%3Dihub International https://www.sciencedire Can therapy with HCQ+AZM reduce the Journal of Safety and effectiveness of azithromycin in patients ct.com/science/article/pi 01‐Oct‐20 RCT Iran Sekhavati et al. NA azithromycine hospital length of stay in COVID‐19 Antimicrobial with COVID‐19: An open‐label randomised trial i/S0924857920303411?v patients? Agents ia%3Dihub Effect of Recombinant Human Granulocyte https://jamanetwork.co Do increased peripheral blood leukocyte Colony–Stimulating Factor for Patients With m/journals/jamainternal and lymphocyte cell counts lead to 10‐Sep‐20 JAMA RCT China Cheng et al. ChiCTR2000030007 G‐CSF Coronavirus Disease 2019 (COVID‐19) and medicine/fullarticle/277 clinical improvement in patients with Lymphopenia: A Randomized Clinical Trial 0680 COVID‐19?

Azithromycin in addition to standard of care versus https://www.thelancet.c standard of care alone in the treatment of patients om/action/showPdf?pii= Would azithromycine improve clinical 04‐Sep‐20 The Lancet RCT Brazil Furtado et al. NCT04321278 azithromycine admitted to the hospital with severe COVID‐19 in Brazil S0140‐ outcomes to COVID‐19 patiets? (COALITION II): a randomised clinical trial 6736%2820%2931862‐6 Is the use of CQ or HCQ effective and Journal Chloroquine and Hydroxychloroquine for the https://link.springer.com safe in reducing mortality and improving Genenral Systematic Arunmozhimaran Chloroquine, 03‐Sep‐20 Treatment of COVID‐19: a Systematic Review and Meta‐ India /article/10.1007/s11606‐ NA the clinical course, fever remission, and Internal review Elavarasi, et al. hydroxychloroquine analysis virologic clearance in COVID‐19 Medicine 020‐06146‐w patients? Diabetes & Metabolic https://www.sciencedire No benefit of hydroxychloroquine in COVID‐19: Results November ‐ Syndrome: Systematic ct.com/science/article/pi Is HCQ effective in milde to moderate of Systematic Review and Meta‐Analysis of India Pathak et al. NA hydroxychloroquine December 2020 Clinical review i/S1871402120303362?v COVID‐19 patients? Randomized Controlled Trials" Research & ia%3Dihub Reviews Naunyn‐ https://link.springer.com Schmiedeberg's Hydroxychloroquine use and progression or prognosis Systematic Benefits and harms of HCQ in COVID‐19 06‐Sep‐20 China Zang et al /article/10.1007%2Fs002 NA hydroxychloroquine Archives of of COVID‐19: a systematic review and meta‐analysis review patients Pharmacology 10‐020‐01964‐5 https://jamanetwork.co m/journals/jama/fullarti Effect of Dexamethasone on Days Alive and Ventilator‐ cle/2770277?utm_camp To determine whether intravenous Free in Patients With Moderate or Severe Acute Bruno M. Tomazini, et aign=articlePDF&utm_m dexamethasone increases the number of 02‐Sep‐20 JAMA RCT Brazil NCT04327401 Dexamethasone Respiratory Distress Syndrome and COVID‐19 The al. edium=articlePDFlink&u ventilator‐free days among patients with CoDEX Randomized Clinical Trial tm_source=articlePDF&u COVID‐19–associated ARDS. tm_content=jama.2020. 17021 https://jamanetwork.co m/journals/jama/fullarti cle/2770279?utm_camp To estimate the association between Association Between Administration of Systemic International aign=articlePDF&utm_m PROSPERO database administration of corticosteroids 02‐Sep‐20 JAMA Corticosteroids and Mortality Among Critically Ill Meta‐analysis Jonathan A.C., et al. Corticosteroids Collaboration edium=articlePDFlink&u (CRD42020197242) compared with usual care or placebo Patients With COVID‐19 ‐ A Meta‐analysis tm_source=articlePDF&u and 28‐day all‐cause mortality. tm_content=jama.2020. 17023 https://jamanetwork.co m/journals/jama/fullarti cle/2770276?utm_camp Effect of Hydrocortisone on 21‐Day Mortality or Does low‐dose hydrocortisone decrease Pierre‐François aign=articlePDF&utm_m 02‐Sep‐20 JAMA Respiratory Support Among Critically Ill Patients With RCT France NCT02517489 Hydrocortisone treatment failure in patients with COVID‐ Dequin, et al. edium=articlePDFlink&u COVID‐19 ‐ A Randomized Clinical Trial 19–related acute respiratory failure? tm_source=articlePDF&u tm_content=jama.2020. 16761 https://jamanetwork.co m/journals/jama/fullarti Effect of Hydrocortisone on Mortality and Organ cle/2770278?utm_camp To determine whether hydrocortisone Support in Patients With Severe COVID‐19 The REMAP‐ aign=articlePDF&utm_m 02‐Sep‐20 JAMA RCT UK Derek C. Angus, et al. NCT02735707 Hydrocortisone improves outcome for patients CAP COVID‐19 Corticosteroid Domain Randomized edium=articlePDFlink&u with severe COVID‐19. Clinical Trial tm_source=articlePDF&u tm_content=jama.2020. 17022 Convalescent plasma in the management of moderate Anup Agarwal et al. To assess the effectiveness of https://www.bmj.com/c CTRI/2020/04/0247 12 October 2020 BMJ COVID‐19 in India: An open‐label parallel‐arm phase II RCT India and PLACID Convalescent plasma Convalescent plasma for the treatment ontent/371/bmj.m3939 75 multicentre randomized controlled trial (PLACID Trial) Collaborators of COVID‐19

https://www.medrxiv.or To demonstrate the efficacy and safety of Convalescent Plasma used to prevent Convalescent Plasma for COVID‐19: A multicenter, g/content/10.1101/2020 01‐Sep MedRxiv RCT Spain Avendaño‐Solà et al. NCT04345523 Convalescent plasma progression to severe disease or death randomized clinical trial .08.26.20182444v3.full.p in hospitalized patients with earlier df forms of COVID‐19 https://www.medrxiv.or Gargling with 1% Early viral clearance among COVID‐19 patients when povidone‐iodine To assess the ability of regular gargling Nurul Azmawati g/content/10.1101/2020 09‐Sep MedRxiv gargling with Povidone‐Iodine and Essential oils ‐ a RCT Malaysia NCT04410159 (Betadine®), essential to eliminate SARS‐CoV‐2 in the Mohamed et al. .09.07.20180448v1.full.p clinical trial. oils (Listerine®) or tap oropharynx and nasopharynx. df water https://www.medrxiv.or To investigate whether tocilizumab has Tocilizumab in Hospitalized Patients With COVID‐19 g/content/10.1101/2020 12/09/2020 MedRxiv RCT USA Rosas et al. NCT04320615 Tocilizumab clinical benefit in hospitalized patients Pneumonia .08.27.20183442v2.full.p with severe COVID‐19 pneumonia. df https://www.sciencedire Efficacy and safety of triazavirin therapy for ct.com/science/article/pi To assess the efficacy of Triazavirin 08‐Sep Engineering coronavirus disease 2019: A pilot randomized RCT China Wu et al. ChiCTR20000300001 Triazavirin i/S2095809920302411?v (TZV) for Covid‐19 controlled trial ia%3Dihub To evaluate the efficacy of treatment Patient‐Reported Health Outcomes After Treatment of https://assets.researchs with intravenous and/or nebulized COVID‐19 with Nebulized and/or Intravenous Neutral quare.com/files/rs‐ BMC Infectious neutral electrolyzed neutral electrolyzed saline combined 10‐Sep Electrolyzed Saline Combined with Usual Medical Care RCT Cuba Delgado‐Enciso et al. 68403/v1/e14a5067‐ RPCEC00000309 Diseases. saline with usual medical care versus usual Versus Usual Medical care alone: A Randomized, Open‐ cd36‐4094‐9c29‐ medical care alone, in ambulatory Label, Controlled Trial. 4bb66ac46805.pdf patients with COVID‐19. https://www.sciencedire Computers in Prediction of respiratory decompensation in Covid‐19 ct.com/science/article/pi 01‐Sep‐20 Biology and RCT USA Burdick et al. NCT04390516 NA NA patients using machine learning: The READY trial i/S0010482520302845?v Medicine ia%3Dihub Journal of Effectiveness of remdesivir for the treatment of https://onlinelibrary.wil 19‐Aug‐20 Medical hospitalized Covid‐19 persons: a network Review China Jiang et al. ey.com/doi/abs/10.1002 NA Remdesivir Remdesivir and its clinical effect Virology meta‐analysis /jmv.26443 Sofosbuvir and daclatasvir compared with standard of https://academic.oup.co Journal of care in the treatment of patients admitted to hospital m/jac/advance‐ IS sofosbuvir and dalatasvir effective in 19‐Aug‐20 Antimicrobial RCT Iran Sadeghi et al. IRCT2020012804629 sofosbuvir/daclatasvir with moderate or severe coronavirus infection (COVID‐ article/doi/10.1093/jac/ COVID patients? Chemotherapy 4N2 19): a randomized controlled trial dkaa334/5889948 https://stemcellres.biom Stem Cell Are human umbilical cord mesenchymal Treatment of severe COVID‐19 with human umbilical edcentral.com/articles/1 umbilical cord 18‐Aug‐20 Research & RCT China Shu et al. ChiCTR2000031494 stem cell infusion effective and safe for cord mesenchymal stem cells 0.1186/s13287‐020‐ mesenchymal stem cells Therapy the treatment of severe COVID? 01875‐5 Journal of "Effect of Calcifediol Treatment and best Available https://www.sciencedire Evaluate the effect of calcifediol on ICU Steroid Therapy versus best Available Therapy on Intensive Marta Entrenas ct.com/science/article/pi admission and mortality among patients October Biochemistry Care Unit Admission and Mortality Among Patients RCT Spain NCT04366908 Calcifediol Castillo, et al. i/S0960076020302764?v hospitalized for COVID‐19 and Molecular Hospitalized for COVID‐19: A Pilot Randomized Clinical Biology study ia%3Dihub Effect of an Inactivated Vaccine Against SARS‐CoV‐2 on https://jamanetwork.co To assess the safety and Vaccine ‐ 13 August 2020 JAMA Safety and Immunogenicity Outcomes Interim Analysis China Shengli Xia, et al. m/journals/jama/fullarti ChiCTR2000031809 Inactivated vaccine immunogenicity of this whole virus Phase I and II of 2 Randomized Clinical Trials cle/2769612 inactivated vaccine https://jamanetwork.co Effect of Remdesivir vs Standard Care on Clinical Status Christoph D. Spinner, Effect of remdesivir in patients with 21 August 2020 JAMA RCT USA m/journals/jama/fullarti NCT04292730 Remdesivir at 11 Days in Patients With Moderate COVID‐19 et al. moderate COVID19 cle/2769871

Drug treatments for covid‐19: living systematic review Systematic International Reed AC Siemieniuk, https://www.bmj.com/c Living systematic review and network 30 July 2020 BMJ NA All treatments and network meta‐analysis Review Collaboration et al. ontent/370/bmj.m2980 meta‐analysis https://www.medrxiv.or Vaccine: RNA vaccines To assess the safety and RNA‐Based COVID‐19 Vaccine BNT162b2 Selected for a g/content/10.1101/2020 28‐Aug MedRXiv RCT USA/ Germany Walsh et al. NCT04368728 BNT162b1 and immunogenicity of varying dose levels of Pivotal Efficacy Study .08.17.20176651v2.full.p BNT162b2 vaccines BNT162b1 and BNT162b2. df Methylprednisolone as Adjunctive Therapy for Patients https://academic.oup.co Clinical Assess the efficacy of short‐term Hospitalized With COVID‐19 (Metcovid): A Christiane Maria m/cid/advance‐ 12 August 2020 Infectious RCT Brazil NCT04343729 Methylprednisolone methylprednisolone in patients with Randomised, Double‐Blind, Phase IIb, Placebo‐ Prado Jeronimo, et al. article/doi/10.1093/cid/ Diseases COVID‐19 Controlled Trial ciaa1177/5891816 https://academic.oup.co Assess the efficacy and safety of Clinical AVIFAVIR for Treatment of Patients with Moderate Andrey A. m/cid/advance‐ favipiravir in moderate COVID19 and 09 August 2020 Infectious COVID‐19: Interim Results of a Phase II/III Multicenter RCT Russia NCT04434248 Favipiravir Ivashchenko, et al. article/doi/10.1093/cid/ select the optimal dosing regimen for Diseases Randomized Clinical Trial ciaa1176/5890024 further evaluation (Phase III). International https://www.sciencedire SARS‐CoV‐2 Clearance in COVID‐19 Patients with Efficacy of Novaferon and Novaferon + Journal of ct.com/science/article/pi Preprint Novaferon Treatment: A Randomized, Open‐label, China Fang Zheng, et al. ChiCTR2000029496 Novaferon Lopinavir/ritonavir in moderate and Infectious i/S120197122030597X?v Parallel Group Trial severe COVID19. Diseases ia%3Dihub https://www.medrxiv.or Telmisartan for treatment of Covid‐19 patients: an Assess the anti‐inflammatory effect of Preprint medRxiv RCT Argentina Mariano Duarte, et al. g/content/10.1101/2020 NCT04355936 Telmisartan open randomized clinical trial. Preliminary report. telmisartan in COVID‐19 patients .08.04.20167205v2 https://ccforum.biomed Auxora versus standard of care for the treatment of central.com/articles/10. Safety and tolerability of auxora in 14 August 2020 Critical Care severe or critical COVID‐19 pneumonia: results from a RCT USA Joseph Miller, et al. NCT04345614. Auxora 1186/s13054‐020‐03220‐ severe or critical COVID‐19 randomized controlled trial x Immunogenicity and Safety of a SARS‐CoV‐2 https://www.medrxiv.or Inactivated Vaccine in Healthy Adults Aged 18‐59 Phase II Is this SARS CoV 2 inactivated vaccine Preprint medRxiv China Yanjun Zhang, et al. g/content/10.1101/2020 NCT04352608 Inactiviated Vaccine years: Report of the Randomized, Double‐blind, and vaccine RCT safe and well tolerated? Placebo‐controlled Phase 2 Clinical Trial .07.31.20161216v1 Beneficial effects of colchicine for moderate to severe https://www.medrxiv.or To evaluate the efficacy of colcihcine in Preprint medRxiv COVID‐19: an interim analysis of a randomized, double‐ RCT Brazil Maria IF Lopes, et al. g/content/10.1101/2020 RBR‐8jyhxh Colchicine treating severe and moderate COVID‐19 blinded, placebo controlled clinical trial .08.06.20169573v2 https://www.nejm.org/d NVX‐CoV2373; Assess the safety and tolerability of the 2 September Phase 1–2 Trial of a SARS‐CoV‐2 Recombinant Spike Phase I NEJM Australia Cheryl Keech, et al. oi/full/10.1056/NEJMoa NCT04368988 recombinant NVX‐COV2373 recombinant vaccine in 2020 Protein Nanoparticle Vaccine vaccine RCT 2026920 nanoparticle vaccine healthy subjects. https://www.nejm.org/d Asses the efficacy of Hydroxychloroquine with or without Azithromycin in Alexandre B. hydroxychloroquine with and without 23 July 2020 NEMJ RCT Brazil oi/10.1056/NEJMoa2019 NCT04322123 Hydroxychloroquine Mild‐to‐Moderate Covid‐19 Cavalcanti, et al. azithromycin in mild to moderate 014 COVID19 Hydroxychloroquine, Journal of Viveksandeep https://onlinelibrary.wil Tocilizumab, Remdesivir, Systematic Review and Meta‐analysis of Effectiveness Systematic Asses overall efficacy of treatments that 6 July 2020 Medical USA Thoguluva ey.com/doi/epdf/10.100 NA convalescent plasma, of Treatment Options Against SARS‐CoV‐2 infection review have been studied thus far. Virology Chandrasekar, et al. 2/jmv.26302 steroids, lopinavir/ritonavir Use of a humanized anti‐CD6 monoclonal antibody https://www.medrxiv.or Is itolizumab a safe and efficient Preprint medRxiv (itolizumab) in elderly patients with moderate COVID‐ CT Cuba Yayquier Díaz, et al. g/content/10.1101/2020 RPCEC00000311 Itolizumab treatment for COVID 19 in elderley 19 .07.24.20153833v1 patients? https://www.medrxiv.or Efficacy and tolerability of bevacizumab in patients Is bevacizumab a safe and efficient Preprint medRxiv CT China, Italy Jiaojiao Pang, et al g/content/10.1101/2020 NCT04275414 Bevacizumab with severe Covid ‐19 treatment for severe COVID 19? .07.26.20159756v1

A clinical pilot study on the safety and efficacy of https://www.sciencedire To evaluate the efficacy and safety of EClinicalMedici 29 July 2020 aerosol inhalation treatment of IFN‐κ plus TFF2 in CT China + USA Weihui et al. ct.com/science/article/pi ChiCTR2000030262 IFN‐κ plus trefoil factor 2 intranasal inhalation of TFF2 and IFN‐κ ne (Lancet) patients with moderate COVID‐19 i/S2589537020302224 protein for SARS‐CoV‐2 infection

A Small‐Scale Medication of Leflunomide as a https://link.springer.com Virologica Is leflunomide effective in COVID‐19 21 July 2020 Treatment of COVID‐19 in an Open‐Label Blank‐ CT China Hu et al. /article/10.1007%2Fs122 ChiCTR 2000030058 leflunomide Sinica patients? Controlled Clinical Trial 50‐020‐00258‐7 https://www.thelancet.c Folegatti et al. on To assess the immunogenicity, Safety and immunogenicity of the ChAdOx1 nCoV‐19 om/journals/lancet/artic behalf of the Oxford ISRCTN 15281137; ChAdOx1 nCoV‐19 reactogenicity, and safety of vaccination 20‐Jul Lancet vaccine against SARS‐CoV‐2: a preliminary report of a RCT UK le/PIIS0140‐ COVID Vaccine Trial NCT04324606 vaccine with ChAdOx1 nCoV‐19 in single‐dose phase 1/2, single‐blind, randomised controlled trial Group 6736(20)31604‐ and two‐dose regimens. 4/fulltext

Immunogenicity and safety of a recombinant https://www.thelancet.c Phase 2 trial to further evaluate the adenovirus type‐5 (Ad5)‐ adenovirus type‐5‐vectored COVID‐19 vaccine in om/action/showPdf?pii= immunogenicity and safety in a larger 20‐Jul Lancet RCT China Feng‐Cai Zhu et al. NCT04341389 vectored COVID‐19 healthy adults aged 18 years or older: a randomised, S0140‐ population, and to determine an vaccine double‐blind, placebo‐controlled, phase 2 trial 6736%2820%2931605‐6 appropriate dose for the efficacy study

https://www.nature.co To assess safety, tolerability, and Phase 1/2 study of COVID‐19 RNA vaccine BNT162b1 in Phase 1/2 immunogenicity of RNA Vaccine 12 August 2020 Nature USA/Germany Mulligan et al. m/articles/s41586‐020‐ NCT04368728 RNA Vaccine BNT162b1 adults trial candidate in a dose escalation study 2639‐4 among healthy adults. https://www.medrxiv.or To complement previous reported data NCT04380701, by providing a detailed characterisation Concurrent human antibody and TH1 type T‐cell Phase 1/2 g/content/10.1101/2020 20‐Jul‐20 Medrxiv Germany/ USA Sahin et al. EudraCT: 2020‐ RNA Vaccine BNT162b1 of antibody and T76 cell immune responses elicited by a COVID‐19 RNA vaccine trial .07.17.20140533v1.full.p 001038‐36 responses elicited by BNT162b1 df vaccination. https://www.nejm.org/d An mRNA Vaccine against SARS‐CoV‐2 — Preliminary To evaluate the safety and 14‐Jul NEMJ Phase 1 trial USA Jackson et al. oi/pdf/10.1056/NEJMoa NCT04283461 mRNA‐1273 vaccine Report immunogenicity of mRNA‐1273 vaccine 2022483 Effect of Hydroxychloroquine in Hospitalized Patients Horby et al. https://www.nejm.org/d To assess the safety and efficacy of ISRCTN 50189673, 08‐Oct NEJM with COVID‐19: Preliminary results from a multi‐centre, RCT UK (RECOVERY oi/10.1056/NEJMoa2022 Hydroxychloroquine hydroxychloroquine in patients NCT04381936 randomized, controlled trial. Collaborative Group) 926 hospitalized with COVID‐19 A Multicenter, randomized, open‐label, controlled trial https://www.medrxiv.or to evaluate the efficacy and tolerability of RCT & To evaluate HCQ efficacy and tolerability g/content/10.1101/2020 10‐Jul Medrxiv hydroxychloroquine and a retrospective study in adult retrospective Taiwan Cheng‐Pin Chen et al. NCT04384380 Hydroxychloroquine in adult patients with mild to moderate .07.08.20148841v1.full.p patients with mild to moderate Coronavirus disease cohort study COVID‐19. 2019 (COVID‐19) df Annals of https://www.acpjournal To investigate whether Hydroxychloroquine in Nonhospitalized Adults With 16‐Jul Internal RCT USA Skipper et al. s.org/doi/10.7326/M20‐ NCT04308668 Hydroxychloroquine hydroxychloroquine could reduce COVID‐ Early COVID‐19 ‐ A Randomized Trial Medicine 4207 19 severity in adult outpatients Is early treatment with Hydroxychloroquine Alone or in Combination with https://papers.ssrn.com hydroxychloroquine (HCQ) with our Hydroxychloroquine, Preprint Lancet Cobicistat‐Boosted Darunavir for Treatment of Mild RTC Spain Mitjà et al, /sol3/papers.cfm?abstra NCT04304053 without cobicistat/darunavir more Darunavir, Cobicistat COVID‐19: A Cluster‐Randomized Clinical Trial ct_id=3615997 efficacious than no‐treatment for outpatients with mild Covid‐19? https://assets.researchs To assess the effcacy and safety of A pragmatic randomized controlled trial reports the quare.com/files/rs‐ hydroxychloroquine therapy on SARS‐ Magnus Nakrem Preprint ResearchSquare efficacy of hydroxychloroquine on coronavirus disease RCT Norway 44055/v1/3fb11155‐ NCT04316377 Hydroxychloroquine CoV‐2 oropharyngeal viral kinetics in Lyngbakken, et al. 2019 viral kinetics d83c‐48a0‐ae74‐ patients hospitalized with moderately b3cce9a5eac3.pdf severe COVID‐19. Open Forum Evaluate the antiviral activity and safety Antiviral Activity and Safety of Darunavir/Cobicistat for https://pubmed.ncbi.nl 11 June 2020 Infectious RCT China Jun Chen, et al. NCT04252274 Darunavir, Cobicistat of darunavir/cobicistat (DRV/c) for the Treatment of COVID‐19 m.nih.gov/32671131/ Diseases treating mild COVID‐19 lopinavir/ritonavir; SN arbidol; Systematic https://link.springer.com To assess the current evidence regarding Comprehensive Systematic and Statistical Review of Coronavirus hydroxychloroquine; 15‐Jul‐20 review & USA Juan A. Siordia Jr et al. /article/10.1007%2Fs423 N/A human controlled COVID‐19 treatment Clinical Disease 19 Treatment Trials remdesivir; tocilizumab; Meta‐analysis trials. Medicine 99‐020‐00399‐6 favipiravir; heparin; dexamethasone

https://www.researchga te.net/profile/Abu_Taiu b_Mohammed_Mohiud din_Chowdhury2/public ation/342159343_A_co mparative_observationa l_study_on_Ivermectin‐ _Doxycycline_and_Hydr Compared outcomes of Ivermectin‐ Abu Taiub Doxycycline vs. Hydroxychloroquine‐ A Randomized Trial of Ivermectin‐Doxycycline and oxychloroquine‐ Ivermectin, Doxycycline, BMC Infectious Mohammed Azithromycin combination therapy Preprint Hydroxychloroquine‐Azithromycin therapy on COVID19 RT Bangladesh Azithromycin_therapy_o NCT04434144 Hydroxychloroquine, Diseases Mohiuddin COVID19 patients with mild to moderate patients. Azithromycin Chowdhury, et al. n_COVID19_patients/lin disease. ks/5f02954c92851c52d6 19d95e/A‐comparative‐ observational‐study‐on‐ Ivermectin‐Doxycycline‐ and‐Hydroxychloroquine‐ Azithromycin‐therapy‐ on‐COVID19‐ patients.pdf

https://www.cochraneli Assess the effectiveness of convalescent Convalescent plasma, updated Convalescent plasma or hyperimmune immunoglobulin Systematic International brary.com/cdsr/doi/10.1 plasma and hyperimmune Cochrane Piechotta V, et al. NA hyperimmune 12/10/20 for people with COVID‐19: a living systematic review review Collaboration 002/14651858.CD01360 immunoglobulin for treating people with immunoglobulin 0.pub2/abstract COVID19

A Randomized, Open‐label, Controlled Clinical Trial https://onlinelibrary.wil Advanced Efficacy of azvudine in treating mild Preprint of Azvudine Tablets in the Treatment of Mild and RCT China Zhigang Ren, et al. ey.com/doi/epdf/10.100 ChiCTR2000029853 Azvudine Science COVID19 patients Common COVID‐19, A Pilot Study 2/advs.202001435

JAMA Network Effect of Colchicine vs Standard Care on Cardiac and https://jamanetwork.co To evaluate the effect of treatment with Open: Inflammatory Biomarkers and Clinical Outcomes in Randomized m/journals/jamanetwor colchicine on cardiac and inflammatory 24/06/2020 Greece Deftereos et al. NCT04326790 Colchicine Infectious Patients Hospitalized With Coronavirus Disease clinical trial kopen/fullarticle/276759 biomarkers and clinical outcomes in Diseases 2019The GRECCO‐19 Randomized Clinical Trial 3 patients hospitalized with COVID‐19. The International Febuxostat Therapy in Outpatients With Suspected https://pubmed.ncbi.nl IRCT2019072704434 Hydroxychloroquine, Is febuxostat effective in comparision 30‐Jun‐20 RCT Iran Davoodi et al. Journal of COVID‐19: A Clinical Trial m.nih.gov/32603531/ N1 febuxostat with hydroxychloroquine? Clinical Practice

https://www.nejm.org/d oi/pdf/10.1056/NEJMoa 2021436?casa_token=H Horby et al. To test the effectiveness of Effect of Dexamethasone in Hospitalized Patients with 8GAcaEgprUAAAAA:m_9 ISRCTN 50189673, 17 July 2020 NEMJ RCT UK (RECOVERY Writing Dexamethasone dexamethasone in patients hospitalized COVID‐19: Preliminary Report Qlb5FCP6d6YPLPMryKLq NCT04381936 Committee) with COVID‐19 VP0QTUouiQsD39ki_1j8 u1syZDvAET7pLjZ3GbCp QSV4V62JZ8086BOdT

To determine whether a 6‐day course of https://www.medrxiv.or intravenous methylprednisolone (MP) GLUCOCOVID: A controlled trial of methylprednisolone g/content/10.1101/2020 EudraCT number: improves outcome in patients with SARS 18‐Jun medRxiv RCT Spain Corral‐Gudino et al. methylprednisolone in adults hospitalized with COVID‐19 pneumonia .06.17.20133579v1.full.p 2020‐001934‐37 CoV‐2 infection at risk of developing df Acute Respiratory Distress Syndrome (ARDS) https://immunology.scie Science Inhibition of Bruton tyrosine kinase in patients with Is acalabrutinib effective in severe 05‐Jun‐20 RCT USA Roschewski et al. ncemag.org/content/5/4 NA Acalabrutinib Immunology severe COVID‐19 COVID‐19 patients? 8/eabd0110 Were the non‐pharmaceutical 8 June 2020 ‐ https://www.nature.co Estimating the effects of non‐pharmaceutical Non‐pharmaceutical interventions implemented in European Accelerated Nature Modelling UK Seth Flaxman, et al. m/articles/s41586‐020‐ NA interventions on COVID‐19 in Europe interventions countries effective in limiting the spread publication 2405‐7 of SARS CoV‐2? https://www.nature.co Nature ‐ The Janus kinase 1/2 inhibitor ruxolitinib in COVID‐19 Retrospective Efficacy and safety of ruxolitinib in 8 May 2020 Germany F. La Rosée, et al. m/articles/s41375‐020‐ Ruxolitinib Leukemia with severe systemic hyperinflammation analysis severe COVID19 0891‐0 https://www.sciencedire Lancet Retrospective Claudio Ucciferri, et ct.com/science/article/pi Is canakinumab a safe and effective 8 June 2020 Canakinumab in a subgroup of patients with COVID‐19 Italy NA Canakinumab Reheumatology analysis al. i/S2665991320301673?v treatment against COVID19? ia%3Dihub Use of personal protective equipment against To examine the protective effects of Observational https://www.bmj.com/c 10‐Jun‐20 BMJ coronavirus disease 2019 by healthcare professionals China Min Liu et al. NA NA appropriate personal protective study ontent/369/bmj.m2195 in Wuhan, China: cross sectional study equipment https://www.thelancet.c Effects of non‐pharmaceutical interventions on COVID‐ om/journals/lanpub/arti What is the impact of different control The Lancet Modelling 02‐Jun‐20 19 cases, deaths, and demand for hospital services in UK Gavines et al. cle/PIIS2468‐ NA NA measures for mitigating the burden of Digital Healt study the UK: a modelling study 2667(20)30133‐ COVID‐19 X/fulltext#%20 Clinical performance of the Luminex NxTAG CoV Journal of https://jcm.asm.org/con Extended Panel for SARS‐CoV‐2 detection in Jonathan Hon‐Kwan Evaluation of Luminex NxTAG in COVID‐ 01‐Jun‐20 Clinical Diagnostic Hong‐Kong tent/early/2020/05/29/J NA Nucleic acid test nasopharyngeal specimens of COVID‐19 patients in Chen 19 detection Microbiology Hong Kong CM.00936‐20 https://www.sciencedire Clinical Clinical evidence for repurposing chloroquine and Systematic ct.com/science/article/pi Hydroxychloroquine, Does hydroxychloroquine have antiviral 26‐May‐20 Microbiology hydroxychloroquine as antiviral agents: a systematic review / Meta‐ Australia/Sri Lanka Rodrigo et al. NA i/S1198743X20302937?v chloroquine effect? and Infection review analysis ia%3Dihub https://www.medrxiv.or To test the performance characteristics Kinetics of the humoral immune response to SARS‐CoV‐ g/content/10.1101/2020 of seven commercially available 14‐Jun MedRxiv 2: comparative analytical performance of seven Diagnostic Belgium Herroelen et al. N/A Antibody test .06.09.20124719v2.full.p serology tests for detection of commercial serology tests df antibodies against the SARS‐CoV‐2 https://www.medrxiv.or To assess the therapeutic efficacy of IFN‐ Therapeutic effectiveness of interferon‐alpha 2b observational g/content/10.1101/2020 09‐Jun MedRxiv Cuba Pereda et al. RPCEC00000318 Interferon alpha 2b α2b in patients infected with SARS‐CoV‐ against COVID‐19: the Cuban experience study .05.29.20109199v1.full.p 2 df https://www.medrxiv.or ICON (Ivermectin in COvid Nineteen) study: Use of To determine whether Ivermectin is Retrospective Cepelowicz Rajter et g/content/10.1101/2020 10‐Jun MedRxiv Ivermectin is Associated with Lower Mortality in USA N/A Ivermectin associated with lower mortality rate in analysis al. .06.06.20124461v2.full.p Hospitalized Patients with COVID19 patients hospitalized with COVID‐19 df To assess the efficacy of lenzilumab prospective https://www.medrxiv.or therapy in patients hospitalized with First Clinical Use of Lenzilumab to Neutralize GM‐CSF study with g/content/10.1101/2020 severe COVID‐19 pneumonia, who had 14‐Jun MedRxiv in Patients with Severe and Critical COVID‐19 FDA USA Temesgen et al. N/A Lenzilumab .06.08.20125369v2.full.p clinical and/or biomarker evidence for Pneumonia emergency increased risk of progression to use IND df respiratory failure. To investigate whether soluble https://www.medrxiv.or urokinase plasminogen activator Low levels of the prognostic biomarker suPAR are prospective g/content/10.1101/2020 receptor (suPAR) can aid in identifying 02‐Jun MedRxiv predictive of mild outcome in patients with symptoms Denmark/USA Eugen‐Olsen et al. N/A Prognostic biomarker cohort study .05.27.20114678v1.full.p patients with low risk of respiratory of COVID‐19 ‐ a prospective cohort study df failure when presenting with symptoms of COVID‐19. https://www.medrxiv.or To determine if Low Dose‐Radiation Low‐Dose Whole‐Lung Radiation for COVID‐19 g/content/10.1101/2020 Therapy can reduce pulmonary 08/06/2020 MedRxiv Pneumonia: Planned Day‐7 Interim Analysis of a CT USA Hess et al. NCT: 04366791 Low dose radiation .06.03.20116988v1.full.p inflammation associated with COVID‐19 Registered Clinical Trial df pneumonia. https://www.medrxiv.or To evaluate the safety and efficacy of Efficacy and Safety of Leflunomide for Refractory g/content/10.1101/2020 02‐Jun MedRxiv CT China Wang et al. ChiCTR2000030058 Leflunomide leflunomide for the treatment of COVID‐19: An Open‐label Controlled Study .05.29.20114223v1.full.p refractory COVID‐19 in adult patients. df https://www.medrxiv.or To explore the effect of high fiber whey Nano short peptide nutrition intervention on the Retrospective g/content/10.1101/2020 08‐Jun MedRxiv China Zhang et al. N/A enteral nutrition short peptide enteral nutrition on the prognosis of patients with COVID‐19 analysis .06.03.20083980v1.full.p prognosis of patients with COVID‐19 df https://www.medrxiv.or To determine if ozonated autohemotherapy is associated with a Ozone therapy for patients with SARS‐COV‐2 prospective g/content/10.1101/2020 05‐Jun MedRxiv Spain/ USA/Canada Hernández et al. N/A Ozone therapy shorter time to clinical improvement in pneumonia: a single‐center prospective cohort study cohort study .06.03.20117994v1.full.p patients with severe COVID‐19 df pneumonia. https://www.medrxiv.or To determine the effect of Center for CIGB‐258 immunomodulatory peptide: a novel Venegas‐Rodriguez et g/content/10.1101/2020 CIGB‐258 immuno‐ Genetic Engineering and Biotechnology 02‐Jun MedRxiv promising treatment for critical and severe COVID‐19 CT Cuba RPCEC00000313 al. .05.27.20110601v1.full.p modulatory peptide (CIGB)‐258 therapy in seriously, or patients df critically ill patients with COVID‐19. A cohort study to evaluate the effect of combination https://www.medrxiv.or To determine the clinical outcomes of Vitamin D, Magnesium and Vitamin B12 (DMB) on Observational g/content/10.1101/2020 Vitamin D, Magnesium older COVID‐19 patients who received 02‐Jun MedRxiv Singapore Chuen Wen Tan et al. N/A progression to severe outcome in older COVID‐19 study .06.01.20112334v1.full.p and Vitamin B12 (DMB) Vitamin D, Magnesium and Vitamin B12 patients. df (DMB) compared to those who did not https://www.medrxiv.or To evaluate differences in morbidity and Therapeutic Anticoagulation Is Associated with mortality among mechanically Retrospective g/content/10.1101/2020 03‐Jun MedRxiv Decreased Mortality in Mechanically Ventilated COVID‐ USA Trinh et al. N/A anticoagulation agents ventilated patients with COVID‐19 analysis .05.30.20117929v1.full.p 19 Patients treated with therapeutic versus df prophylactic anticoagulation

https://translational‐ EudraCT (2020‐ Tocilizumab for patients with COVID‐19 pneumonia. medicine.biomedcentral. 001110‐38); To evaluate efficacy of tocilizumab in 21 October 2020 of Translational M CT Italy Perrone et al. Tocilizumab The TOCIVID‐19 phase 2 trial com/articles/10.1186/s1 clinicaltrials.gov COVID‐19 pneumonia patients. 2967‐020‐02573‐9 (NCT04317092)

prospective https://www.medrxiv.or To compare SAMBA II SARS‐CoV‐2 Rapid point of care nucleic acid testing for SARS‐CoV‐2 clinical trial performance against the standard lab g/content/10.1101/2020 02/06/2020 MedRxiv in hospitalised patients: a clinical trial and and UK/South Africa Dami Collier, et al. NCT04326387 Nucleic acid diagnostic RTPCR test in suspected COVID‐19 cases .05.31.20114520v1.full.p implementation study observational presenting to hospital, followed by a study df hospital‐based implementation study.

To compare three fully automated large‐ https://www.medrxiv.or scale laboratory analyzer test systems, Side by side comparison of three fully automated SARS‐ Diagnostic g/content/10.1101/2020 with particular emphasis on specificity, 06‐Jun MedRxiv Austria Perkmann et al. N/A Antibody diagnostic CoV‐2 antibody assays with a focus on specificity comparison .06.04.20117911v2.full.p which is crucial for an adequate positive df predictive value given the current low seroprevalence worldwide.

https://www.medrxiv.or To describe initial experience using a Implementation and evaluation of a novel real‐time Diagnostic commercially‐available multiplex two‐ g/content/10.1101/2020 05‐Jun MedRxiv multiplex assay for SARS‐CoV‐2: In‐field learnings from validation Australia Williams et al. N/A Nucleic acid diagnostic step nested tandem RT‐PCR assay for .06.03.20117267v1.full.p a clinical microbiology laboratory study the detection of coronaviruses that df infect humans, including SARS‐CoV‐2

https://www.medrxiv.or Diagnostic for To construct and validate a cell‐free Diagnostic Detection of SARS‐CoV‐2 neutralizing antibodies with a g/content/10.1101/2020 indentifying suitable assay to measure neutralizing antibodies 02‐Jun MedRxiv validation USA/Switzerland Danh et al. N/A cell‐free PCR assay .05.28.20105692v1.full.p Convalescent plasma in order to identify suitable donors of study df donors convalescent plasma https://www.medrxiv.or diagnostic To evaluate the real‐world diagnostic Diagnostic accuracy of a host response point‐of‐care g/content/10.1101/2020 02‐Jun MedRxiv clinical UK Clark et al. ISRCTN14966673 Diagnostic accuracy of FebriDx for the identification test for identifying COVID‐19 .05.27.20114512v1.full.p evaluation of COVID‐19 in hospitalised adults df https://www.sciencedire Alltest rapid lateral flow immunoassays is reliable in To analyze the diagnostic performance Journal of Diagnostic ct.com/science/article/pi August 2020 diagnosing SARS‐CoV‐2 infection from 14 days after Spain García et al. NA NA of one serologic rapid test in COVID‐19 Clinical Virology assay i/S1386653220302158?v symptom onset: A prospective single‐center study patients ia%3Dihub Poor‐sleep is associated with slow recovery from Brain, https://www.sciencedire Effects of sleep quality on recovery from lymphopenia and an increased need for ICU care in Retrospective 06‐Jun‐20 Behaviour and China Zhang et al. ct.com/science/article/pi NA NA lymphopenia and clinical outcomes in hospitalized patients with COVID‐19: A retrospective study Imunity hospitalized patients with COVID‐19 cohort study i/S0889159120309946 To assess the overall benefit–risk of the Remdesivir in Treatment of COVID-19: A Systematic Systematic https://doi.org/10.1007/ use of remdesivir as a treatment for 28 May 2020 Drug Safety UK Miranda Davies, et al. NA Remdesivir Benefit–Risk Assessment review s40264‐020‐00952‐1 COVID‐19 compared with standard of care, placebo or other treatments To determine the frequency of venous Routine Venous Thromboembolism Prophylaxis May DOI: Venous Society of Observational Thomas K. Maatman, thromboembolism (VT) in critically ill 27 May 2020 Be Inadequate in the Hypercoagulable State of Severe USA 10.1097/CCM.00000000 NA thromboembolism Critical Care study et al. COVID19 patients who recieved Coronavirus Disease 2019 prophylaxis 00004466 prophylaxis for VT. Effect of Convalescent Plasma Therapy on Time to doi:10.1001/jama.2020. Is convalescent plasma a safe and 3 June 2020 JAMA Clinical Improvement in Patients With Severe and Life‐ RCT China Ling Li, et al. ChiCTR2000029757 Convalescent Plasma 10044 efficient treatment for severe COVID19? threatening COVID‐19 ‐ A Randomized Clinical Trial

Journal of the https://www.sciencedire American Retrospective Ignacio J. Amat‐ ct.com/science/article/pi NCT03201185 To analyze if ramipril modifies the risk Preprint Ramipril in High Risk Patients with COVID‐19 Spain Ramipril College of analysis Santos, et al. i/S073510972035395X?v (source RCT) for COVID‐19. Cardiology ia%3Dihub Should health care workeers wear The need of health policy perspective to protect https://journals.plos.org surgical masks or N95 respirators during Systematic Healthcare Workers during COVID‐19 pandemic. A Primiano Iannone, et /plosone/article?id=10.1 the routine care (not 3 June 2020 PlosOne review / Meta‐ Italy NA N95 respirators GRADE rapid review on the N95 respirators al. 371/journal.pone.02340 involving aerosol generating analysis effectiveness 25 procedures) of COVID‐19 suspected or affected patients? Investigate the effects of physical Physical distancing, face masks, and eye protection to distance, face masks, and eye protection Systematic International https://doi.org/10.1016/ PROSPERO: 1 June 2020 Lancet prevent person‐to‐person transmission of SARS‐CoV‐2 Derek K Chu, et al. PPE on virus transmission in health‐care and review collaboration S0140‐6736(20)31183‐1 CRD42020177047 and COVID‐19: a systematic review and meta‐analysis non‐health‐care (eg, community) settings Diabetes, Exposure to DPP‐4 inhibitors and COVID‐19 among Case Gian Paolo Fadini, et https://pubmed.ncbi.nl Do DPP‐4 inhinbitors have a protective Preprint obesity & people with type 2 population Italy NA DPP‐4 inhibitors al. m.nih.gov/32463179/ effect agains COVID19? metabolism diabetes. A case‐control study study https://www.nejm.org/d A Randomized Trial of Hydroxychloroquine as Is hydroxychloroquine effective in post‐ 03 June 2020 NEJM RCT USA / Canada D.R. Boulware, et al. oi/full/10.1056/NEJMoa NCT04308668. Hydroxychloroquine Postexposure Prophylaxis for Covid‐19 exposure prohylaxis therapy? 2016638 Can CRISPR technology simplify RT‐PCR Biosensors and Ultra‐sensitive and high‐throughput CRISPR‐Powered Diagnostic https://doi.org/10.1016/ Preprint USA Zhen Huang, et al. NA CRISPR RT‐PCR for SARS CoV2 and be effective for Bioelectronics COVID‐19 diagnosis assay j.bios.2020.112316 diagnos? https://www.gastrojour Famotidine Use is Associated with Improved Clinical Do COVID19 patients taking famotidine Gastroenterolo Retrospective Daniel E. Freedberg, nal.org/article/S0016‐ Preprint Outcomes in Hospitalized COVID‐19 Patients: A USA NA Famotidine have a lower risk of intubation and/or gy study et al. 5085(20)34706‐ Propensity Score Matched Retrospective Cohort Study death? 5/fulltext International https://www.nejm.org/d Is a 5 day course of remedesivir as Remdesivir for 5 or 10 Days in Patients with Severe Jason D. Goldman, et 27 May 2020 NEJM RCT collaboration/ Gilead oi/full/10.1056/NEJMoa NCT04292899 Remdesivir effective as a 10 course in treating Covid‐19 al. Sciences 2015301 moderately ill COVID19 patients? https://www.nejm.org/d Is remdesivir an effective treatment for Remdesivir for the Treatment of Covid‐19 — International 22 May 2020 NEJM RCT J.H. Beigel, et al. oi/full/10.1056/NEJMoa NCT04280705 Remdesivir reducing time to recovery in COVID19 Preliminary Report collaboration 2007764 patients? Journal of Ruxolitinib in treatment of severe coronavirus disease To evaluate the efficacy and safety of Allergy and https://doi.org/10.1016/ ChiCTR‐OPN‐ Preprint 2019 (COVID‐19): A multicenter, single‐blind, RCT China Yang Cao, et al. Ruxolitinib ruxolitinib for patients with severe Clinical j.jaci.2020.05.019 2000029580. randomized controlled trial COVID19. Immunology Clinical Thymosin alpha 1 (Tα1) reduces the mortality of severe Retrospective https://pubmed.ncbi.nl Is thymosin alpha a safe and effective Preprint Infectious COVID 19 by restoration of lymphocytopenia and China Yueping Liu, et al. NA Thymosin alpha study m.nih.gov/32442287/ treatment for severe COVID19? Diseases reversion of exhausted T cells

International https://www.sciencedire Level of protection confered by masks Journal of HUMAN CORONAVIRUS DATA FROM FOUR CLINICAL C Raina MacIntyre, et Preprint Review Australia ct.com/science/article/pi NA PPE and respirators for common Infectious TRIALS OF MASKS AND RESPIRATORS al. coronavirus. Diseases i/S1201971220303994 https://www.thelancet.c om/journals/lanrhe/artic Use of anakinra in patients who were The Lancet 29‐May‐20 Anakinra for severe forms of COVID‐19: a cohort study Cohort study France Huet et al. le/PIIS2665‐ NA Anakinra admitted to hospital for severe forms of Rheumatology 9913(20)30164‐ COVID‐19 8/fulltext https://www.thelancet.c Safety, tolerability, and immunogenicity of a om/journals/lancet/artic Are different doses of Ad5 vectored recombinant adenovirus type‐5 vectored COVID‐19 Ad5 vectored COVID‐19 22‐May‐20 The Lancet CT China Feng‐Cai Zhu et al. le/PIIS0140‐ NCT04313127 COVID‐19 vaccine safe and vaccine: a dose‐escalation, open‐label, non‐ vaccine immunogenic? randomised, first‐in‐human trial 6736(20)31208‐ 3/fulltext A comparative study on the time to achieve negative https://www.researchsq nucleic acid testing and hospital stays between Comparative Danopevir and Antiviral effect of danopevir or 29‐May‐20 Preprint China Zhicheng Zhang et al. uare.com/article/rs‐ NA Danoprevir and Lopinavir/Ritonavir in the treatment of study lopinavir/ritonavir lopinavir/ritonavir in COVID‐19 patients patients with COVID‐19 28376/v1.pdf

Potential of Arbidol for Post‐exposure Prophylaxis of https://link.springer.com Current Medical Observational Is Arbidol effective in profylaxis of 01‐Jun‐20 COVID‐19 Transmission–A Preliminary Report of a China Zhang et al. /content/pdf/10.1007/s NA Arbidol Science study COVID? Retrospective Cohort Study 11596‐020‐2203‐3.pdf

Advanced http://ajem.tums.ac.ir/in Journal of Interferon beta‐1a as a Candidate for COVID‐19 IRCT2015091402401 Is interferon beta1a effective in 26‐May‐20 CT Iran Payandemehr et al. dex.php/ajem/article/vie Interferon beta1a Emergency Treatment; An Open‐label Single‐Arm Clinical Trial 7N1 treatment of COVID‐19? Medicine w/454/307 https://aac.asm.org/con Efficacy and safety of interferon beta‐1a in treatment Davoudi‐Monfared et IRCT2010022800344 To evaluate efficacy and safety of IFN β‐ 13 July 2020 Antiviral Agents RCT Iran tent/early/2020/07/08/ Interferon beta‐1a of severe COVID‐19: A randomized clinical trial al. 9N28 1a in patients with severe COVID‐19. AAC.01061‐20 Clinical https://www.medrxiv.or To develop and clinically evaluate an at‐ A serological assay to detect SARS‐CoV‐2 antibodies in Evaluation of g/content/10.1101/2020 IRB protocol 30/05/2020 medRxiv USA Karp et al. Antibody diagnostic test home finger‐prick dried blood spot test at‐home collected fingerprick dried blood spots diagnostic .05.29.20116004v2.full.p #20180015 to detect SARS‐CoV‐2 antibodies test df Clinical https://www.medrxiv.or To assess the analytical and clinical Performance evaluation of the point‐of‐care SAMBA II Evaluation of g/content/10.1101/2020 Nucleic acid diagnostic performance of the SAMBA II 83 SARS‐ 27/05/2020 medRxiv UK/USA/South Africa Assennato et al. N/A SARS‐CoV‐2 Test for detection of SARS‐CoV‐2 diagnostic .05.24.20100990v2.articl test CoV‐2 Test using panels and clinical test e‐info samples. Clinical https://www.medrxiv.or To develop and clincally evaluate a new EasyCOV : LAMP based rapid detection of SARS‐CoV‐2 Evaluation of g/content/10.1101/2020 saliva RT‐LAMP 30/05/2020 medRxiv France L’Helgouach et al. N/A simple saliva SARS‐CoV‐2 detection test in saliva diagnostic .05.30.20117291v1.full.p diagnostic test based on RT‐LAMP technology test df Clinical https://www.medrxiv.or To evaluate the performance of two Evaluation of performance of two SARS‐CoV‐2 Rapid Evaluation of g/content/10.1101/2020 Antibody rapid COVID 19 IgM/IgG Rapid Diagnostic 27/05/2020 medRxiv whole‐blood finger‐stick IgM‐IgG Combined Antibody France Prazuck et al. N/A diagnostic .05.27.20112888v1.full.p diagnostic test Tests compared to the gold standard, RT‐ Tests test df PCR. https://www.medrxiv.or To show the potential efficacy and Mortality reduction in 46 severe Covid‐19 patients safety of hyperimmune plasma proof of g/content/10.1101/2020 29/05/2020 medRxiv treated with hyperimmune plasma. A proof of concept Italy Perotti et al. NCT 04321421 convalescent plasma infusions, obtained from convalescent concept study .05.26.20113373v1.full.p single arm multicenter interventional trial donors, in COVID‐19 patients with df respiratory failure https://www.medrxiv.or To analyse the outcomes of COVID‐19 Use of High Flow Nasal Therapy to Treat Moderate to Retrospective g/content/10.1101/2020 patients with moderate‐to‐severe 26/05/2020 medRxiv USA Patel et al. High Flow Nasal Therapy Severe Hypoxemic Respiratory Failure in COVID‐19 analysis .05.22.20109355v1.full.p hypoxemic respiratory failure receiving df High Flow Nasal Therapy https://www.thelancet.c Hydroxychloroquine or chloroquine with or without a om/journals/lancet/artic Observational Are these treatment regimens 22‐May‐20 The Lancet with or without a macrolide for treatment of COVID‐ USA/Switzerland Mehra et al. le/PIIS0140‐ NA Hydroxychloroquine study associated with in‐hospital death? 19: a multinational registry analysis 6736(20)31180‐ 6/fulltext

https://www.frontiersin. Is Interferon‐a2b efficient in accelerating Frontiers in 15 May 2020 Interferon‐a2b Treatment for COVID‐19 CT Canada, China Qiong Zhou, et al. org/articles/10.3389/fim NA Interferon‐a2b viral clearance and reducing Immunology mu.2020.01061/full inflammation markers? https://www.medrxiv.or Clinical To examine the role of early Early Short Course Corticosteroids in Hospitalized Retrospective g/content/10.1101/2020 19 May 2020 Infectious USA Fadel et al. NCT04374071 corticosteroids corticosteroid therapy in patients with Patients with COVID‐19 study .05.04.20074609v1.full.p Diseases moderate to severe COVID‐19. df https://www.medrxiv.or Convalescent plasma treatment of severe COVID‐19: A Is convalescent plasma an effective Preprint medRxiv CT USA Sean T. H. Liu, et al. g/content/10.1101/2020 NA Convalescent plasma matched control study treatment for severe COVID19? .05.20.20102236v1 https://www.thelancet.c Use of renin–angiotensin–aldosterone system Case om/journals/lancet/artic renin–angiotensin–aldos Francisco J de Abajo, Does use of RAAS predispose patients to 14 May 2020 Lancet inhibitors and risk of COVID‐19 requiring admission to population Spain le/PIIS0140‐ EUPAS34437 terone system inhibitors, et al. severe COVID19? hospital: a case‐population study study 6736(20)31030‐ RAAS 8/fulltext To evaluate various methods of chest compressions in patients with Resuscitation of the patient with suspected/confirmed Randomized https://journals.viamedi suspected/confirmed SARS‐CoV‐2 Cardiology COVID‐19 when wearing personal protective Preprint crossover Poland Marek Malysz, et al. ca.pl/cardiology_journal NA PPE infection conducted by medical students Journal equipment: A randomized multicenter crossover trial wearing full personal protective simulation trial /article/view/68336 equipment (PPE) for aerosol generating procedures (AGP). Stefano Bonovas, https://www.nejm.org/d Compassionate Use of Remdesivir in Covid‐19 (Grein et Letters to the Gerd Fätkenheuer, Re‐analysis of cumulative incidence of 15 May 2020 NEJM International oi/full/10.1056/NEJMc2 NA Remdesivir al. ‐ NEMJ) editor Christian Hoffman, improvement, patient classification Jiayuan Wu 015312 https://www.clinicalmicr To evaluate the performance of an ultra‐ Clinical Diagnostic obiologyandinfection.co A multiple center clinical evaluation of an ultra‐fast fast single‐tube nucleic acid isothermal Preprint Microbiology clinical China Ji Wang, et al. m/action/showPdf?pii=S NA Diagnostic test single‐tube assay for SARS‐CoV‐2 RNA amplification detection assay for SARS‐ and Infection evaluation 1198‐ CoV‐2 RNA 743X%2820%2930284‐6

Are combined oropharyngeal/nares A combined oropharyngeal/nares swab is a suitable Diagnostic https://www.sciencedire Oropharyngeal/nares Journal of swab is a suitable alternative for Preprint alternative to nasopharyngeal swabs for the detection assay Canada Jason J., et al. ct.com/science/article/pi NA and nasopharyngeal Clinical Virology nasopharyngeal swabs for COVID19 of SARS‐CoV‐2 comparison swabs i/S1386653220301840 sample colleciton? Can an AI model rapidly identify SARS‐ https://www.nature.co CoV‐2 infection based on initial chest CT Artificial intelligence–enabled rapid diagnosis of Diagnostic 19 May 2020 Nature Chinq Xueyan Mei, et al. m/articles/s41591‐020‐ N/A AI diagnostic algorithm scans and associated clinical information patients with COVID‐19 assay 0931‐3 of COVID‐19 (+) patients in the early stage? To investigate the effects of dipeptidyl https://www.medrxiv.or dipeptidyl peptidase‐4 Effects of a DPP‐4 inhibitor and RAS blockade on peptidase‐4 (DPP‐4i) and retrospective g/content/10.1101/2020 (DPP‐4i), 23‐May Medrxiv clinical outcomes of patients with diabetes and COVID‐ South Korea Sang Youl Rhee et al. N/A renin–angiotensin system (RAS) analysis .05.20.20108555v1.full.p renin–angiotensin 19 blockade on the short‐term clinical system (RAS) blockade df outcomes of COVID‐19 https://www.medrxiv.or To investigate the prevalence of Do COVID‐19 patients admitted to the ICU require anti‐ prospective g/content/10.1101/2020 anti‐Pneumocystis 22‐May Medrxiv France Alanio N/A Pneumocystis jirovecii in COVID‐19 Pneumocystis jirovecii prophylaxis? cohort study .05.18.20105296v1.full.p jirovecii prophylaxis patients admitted to the ICU df To develop and validate a novel RT‐ Development and clinical application of a rapid and https://www.medrxiv.or LAMP assay capable of detecting SARS‐ 23/05/2020 Medrxiv sensitive loop‐mediated isothermal amplification test Diagnostic China Hu et al. g/content/10.1101/2020 N/A RT‐LAMP Diagnostic test CoV‐2 RNA for potential use in for SARS‐CoV‐2 infection .05.20.20108530v2 centralized facilities and point‐of‐care settings https://www.medrxiv.or Use of siltuximab in patients with COVID‐19 retrospective g/content/10.1101/2020 Efficacy of siltuximab for treatment of 22 May 2020 Medrxiv Italy, UK Gritti et al. NCT04322188 siltuximab pneumonia requiring ventilatory support analysis .04.01.20048561v3.full.p severe patients with COVID‐19 df https://www.medrxiv.or To test if intravenous almitrine can Almitrine as a non ventilatory strategy to improve Case control g/content/10.1101/2020 22‐May Medrxiv France Losser et al. N/A Almitrine improve hypoxia in mechanically intrapulmonary shunt in COVID‐19 patients series .05.18.20105502v1.full.p ventilated COVID‐19 patients. df https://www.medrxiv.or To examine the benefit‐risk profile of Systematic Remdesivir in treatment of COVID‐19: A systematic g/content/10.1101/2020 remdesivir in COVID‐19 patients 12‐May MedRxiv benefit‐risk UK Davies et al. N/A Remdesivir benefit‐risk assessment .05.07.20093898v1.full.p compared to standard assessment df of care, placebo or other treatments. Application of https://www.medrxiv.or deep learning To test the hypothesis that application Assisting Scalable Diagnosis Automatically via CT g/content/10.1101/2020 15‐May MedRxiv to China Liu et al. N/A Chest CT of deep learning to 3D chest CT images Images in the Combat against COVID‐19 .05.11.20093732v1.full.p retrospective could help identify COVID‐19 infections. analysis df https://www.medrxiv.or To explore the association of ACEi/ARB The effects of ARBs, ACEIs and statins on clinical retrospective g/content/10.1101/2020 and/or statins with clinical 15‐May MedRxiv outcomes of COVID‐19 infection among nursing home Belgium De Spiegeleer et al. N/A ARBs, ACEi, Statins analysis .05.11.20096347v1.full.p manifestations in COVID‐19 infected residents df older people residing in nursing homes. https://www.medrxiv.or To analyse key safety metrics following expanded Early Safety Indicators of COVID‐19 Convalescent g/content/10.1101/2020 transfusion of convalescent plasma in 14‐May MedRxiv access USA Joyner et al. NCT04338360 Convalescent plasma Plasma in 5,000 Patients patients with severe or life‐threatening program .05.12.20099879v1.full.p df COVID‐19

https://www.medrxiv.or To report the clinical course, safety, and Nebulized in‐line endotracheal dornase alfa and Nebulized in‐line outcomes after nebulized in‐line retrospective g/content/10.1101/2020 15‐May MedRxiv albuterol administered to mechanically ventilated USA Weber et al. NCT04387786 endotracheal Dornase endotracheal dornase alfa treatment for case study .05.13.20087734v1.full.p COVID‐19 patients: A case series Alfa intubated and mechanically ventilated df patients with COVID‐19. https://www.medrxiv.or To determine if transfusion of Treatment of COVID‐19 Patients with Convalescent g/content/10.1101/2020 convalescent plasma is a safe treatment 13‐May MedRxiv Case series USA Salazar et al. N/A Convalescent plasma Plasma in Houston, Texas .05.08.20095471v1.full.p option for those with severe COVID‐19 df disease. http://viruseradication.c om/journal‐ details/A_review_of_the Journal of Virus A review of the safety of favipiravir – a potential Systematic Victoria Pilkington, et 30 April 2020 UK _safety_of_favipiravir_% NA Favipiravir Safety of favipiravir Eradication treatment in the COVID‐19 pandemic? review al. E2%80%93_a_potential_ treatment_in_the_COVI D‐19_pandemic%5E/ To evaluate the safety and impact of Allogeneic cardiosphere-derived cells (CAP-1002) in https://link.springer.com administration of allogeneic CDCs, Basic Research 12 May 2020 critically ill Case series USA Siddharth Singh, et al. /article/10.1007/s00395‐ NA CAP‐1002 formulated for intravenous (IV) in Cardiology COVID-19 patients: compassionate-use case series 020‐0795‐1 infusion as CAP‐1002, in critically ill COVID‐19 patients. Efficacy and safety of corticosteroids in COVID‐19 Canadian https://www.cmaj.ca/co based on evidence for COVID‐19, other coronavirus Systematic Assess efficacy and safety of Medical International ntent/cmaj/early/2020/ Preprint infections, influenza, community‐acquired pneumonia Review ; Zhikang Ye, et al. NA Corticosteroids corticosteroids for COVID19, SARS, Association Collaboration 05/14/cmaj.200645.full. and acute respiratory distress syndrome: a systematic Meta‐analysis MERS, CAP, ARDS and influenza Journal review and meta‐analysis pdf Clinical and Pilot prospective open, single‐arm multicentre study https://www.clinexprhe To assess the efficacy and safety of 1 May 2020 Experimental on off‐label use of tocilizumab in patients with severe CT Italy S. Sciascia, et al. umatol.org/abstract.asp NA Tocilizumab tocilizumab in severe COVID19 patients Rheumatology COVID‐19 ?a=15723 Efficacy of different facial protection BMJ Global Facial protection for healthcare workers during Scoping Laura R Garcia Godoy, https://gh.bmj.com/cont 23 April 2020 USA NA Facial protection devices, especially in light of N95 Health pandemics: a scoping review Review et al. ent/5/5/e002553 respirator shortages Compassionate remdesivir treatment of severe Covid‐ Pharmacologica 19 pneumonia in intensive care unit (ICU) and Non‐ICU Spinello Antinori, et https://pubmed.ncbi.nl Comparative efficacy of remdesivir in Preprint Case series Italy NA Remdesivir l Research patients: Clinical outcome and differences in post al. m.nih.gov/32407959/ ICU and non‐ICU patients treatment hospitalisation status

To evaluate which type of full‐body PPE Personal protective equipment for preventing highly https://www.cochraneli and which method of donning or do.ing Cochrane infectious diseases due to exposure to contaminated Systematic International brary.com/cdsr/doi/10.1 PPE have the least risk of contamination 15 April 2020 Verbeek JH, et al. NA PPE Library body fluids in healthcare Review Collaboration 002/14651858.CD01162 or infection for HCW, and which training staff 1.pub4/full methods increase compliance with PPE protocols.

https://www.cochraneli To assess whether convalescent plasma Cochrane Convalescent plasma or hyperimmune immunoglobulin Systematic brary.com/cdsr/doi/10.1 or hyperimmune immunoglobulin 14 May 2020 Netherlands Valk SJ, et al. NA Convalescent Plasma Library for people with COVID‐19: a rapid review Review 002/14651858.CD01360 transfusion is eJective and safe in the 0/full treatment of people with COVID‐19. Journal of https://www.jacionline. Preliminary assessment of the safety Allergy and Safety and efficacy of early high‐dose IV anakinra in Emanuele Pontali, et org/article/S0091‐ Preprint Case series Italy NA Anakinra and efficacy of anakirna in Clinical severe COVID‐19 lung disease al. 6749(20)30634‐ severe/moderate COVID19 Immunology 5/fulltext Tocilizumab for Treatment of Severe COVID‐19 Observational https://pubmed.ncbi.nl What is the role of tocilizumab therapy 09 May 2020 Microorganisms Patients: Preliminary Results From SMAtteo COvid19 Italy Colaneri et al. NA tocilizumab study m.nih.gov/32397399/ in severe COVID‐19 patients? REgistry (SMACORE) Hydroxychloroquine in Patients With Mainly Mild to https://www.bmj.com/c Is hydroxychloroquine effective and safe 14 May 2020 BMJ Moderate Coronavirus Disease 2019: Open Label, RCT China Tang et al. ontent/369/bmj.m1849.l ChiCTR2000029868 Hydroxychloroquine in COVID‐19 patients? Randomised Controlled Trial ong Clinical efficacy of hydroxychloroquine in patients with covid‐19 pneumonia who require oxygen: Observational https://www.bmj.com/c 05 May 2020 BMJ France Mahévas et al. NA Hydroxychloroquine Is hydroxychloroquine effective? observational comparative study using routine care study ontent/369/bmj.m1844 data To assess and compare the performance Clinical https://www.medrxiv.or Detection of SARS‐CoV‐2 antibodies using commercial of 6 rapid tests and 3 ELISAs for the Evaluation of g/content/10.1101/2020 08 May 2020 MedRxiv assays and seroconversion patterns in hospitalized France Tuaillon et al. NCT04347850 Antibody diagnostic test diagnosis of COVID‐19, and to explore diagnostic .05.04.20090027v3.full.p patients seroconversions in subjects with test df confirmed COVID‐19

Clinical https://www.medrxiv.or To compare the dynamic range and the ddPCR: a more sensitive and accurate tool for SARS‐ evaluation of g/content/10.1101/2020 08 May 2020 MedRxiv China Suo et al. PCR diagnostic test limit of detection (LoD) between ddPCR CoV‐2 detection in low viral load specimens diagnostic .02.29.20029439v2.full.p and RT‐PCR test df https://www.medrxiv.or To evaluate the efficacy and safety of Clinical Outcomes and Plasma Concentrations of g/content/10.1101/2020 baloxavir marboxil, adding baloxavir marboxil or favipiravir 05 May 2020 MedRxiv Baloxavir Marboxil and Favipiravir in COVID‐19 RCT China Yan Lou et al. ChiCTR2000029544 .04.29.20085761v1.full.p favipiravir to the current standard antiviral Patients: an Exploratory Randomized, Controlled Trial df treatment https://www.medrxiv.or To determine if excessive PGE2 may be Celebrex adjuvant therapy on COVID‐19: An g/content/10.1101/2020 a key in the pathology of COVID‐19 and 11 May 2020 MedRxiv Clinical trial China Wenxin Hong et al. ChiCTR2000031630 Celebrex (Celecoxib) experimental study .05.05.20077610v1.full.p whether COX‐2 is a critical target for df therapy. retrospective https://www.medrxiv.or To take into account the possible analysis of confounders when analyzing the COVID‐19 Related Mortality: Is the BCG Vaccine Truly g/content/10.1101/2020 05 May 2020 MedRxiv International Mexico Paredes et al. N/A BCG difference in mortality rates between Effective? .05.01.20087411v1.full.p mortality countries with and without history of a rates df universal BCG vaccination program.

https://www.medrxiv.or zinc sulfate (as add‐on To determine if zinc sulfate added to Hydroxychloroquine and azithromycin plus zinc vs retrospective g/content/10.1101/2020 therapy to hydroxychloroquine and azithromycin 08 May 2020 MedRxiv hydroxychloroquine and azithromycin alone: outcomes observational USA Carlucci et al. N/A .05.02.20080036v1.full.p hydroxychloroquine and may improve outcomes among in hospitalized COVID‐19 patients study df azithromycin) hospitalized patients. https://www.medrxiv.or To evaluate the effectiveness of the use Systematic Efficacy of face mask in preventing respiratory virus g/content/10.1101/2020 of masks to prevent laboratory‐ 05 May 2020 MedRxiv review and China Liang et al. N/A facemask transmission: a systematic review and meta‐analysis .04.03.20051649v3.full.p confirmed respiratory virus meta‐analysis df transmission. Impact of corticosteroid therapy on outcomes of https://www.nature.co Evaluate the safety and efficacy of Meta‐ 5 May 2020 Nature persons with SARS‐CoV‐2, SARS‐CoV, or MERS‐CoV China Huan Li, et al. m/articles/s41375‐020‐ NA Corticosteroids corticosteroids on SARS‐CoV‐2, SARS‐ analyisis infection: a systematic review and meta‐analysis 0848‐3.pdf CoV, and MERS‐CoV infections Journal of https://www.biorxiv.org Can an efficient in‐silico trial base be Biomedical and In Silico Trial to test COVID‐19 candidate vaccines: a Giulia Russo, Preprint Italy Giulia Russo, et al. /content/10.1101/2020. NA Vaccine developed, and can it evaluate vaccine Health case study with UISS platform et al. candidates? Informatics 05.06.080630v1.full.pdf Were non‐pharmaceutical interventions Effect of non‐pharmaceutical interventions to contain https://www.nature.co Mathematical Non‐pharmaceutical effective in reducing the number of Preprint Nature COVID‐19 in China China, UK, US Shengjie Lai, et al. m/articles/s41586‐020‐ NA Modeling interventions cases and speed of the epidemic in 2293‐x_reference.pdf mainland China?

Continuous hydroxychloroquine or colchicine therapy https://www.ncbi.nlm.ni Protective role of colchicine or Autoimmunity Retrospective Omer Gendelman, et Colchicine, 29 April 2020 does not prevent infection with SARS‐CoV‐2: Insights Israel h.gov/pmc/articles/PMC NA hydroxychloriquine for COVID19 Reviews analysis al. hydroxychloroquine from a large healthcare database analysis 7198406/ infection Tocilizumab for the treatment of severe COVID‐19 https://www.sciencedire Is tocilizumab effective for improving Autoimmunity pneumonia with hyperinflammatory syndrome and Observational ct.com/science/article/a Preprint Italy Paola Toniati, et al. NA Tocilizumab respiratory condition in severe Reviews acute respiratory failure: A single center study of 100 study bs/pii/S1568997220301 COVID19? patients in Brescia, Italy 300 https://www.pnas.org/c Effective treatment of severe COVID‐19 patients with Retrospective ontent/pnas/early/2020 Efficacy and safety of tocilizumab in April 29 2020 PNAS China Xiaoling Xua, et al. Tocilizumab tocilizumab analysis /04/27/2005615117.full. sever COVID19 pdf https://www.thelancet.c Triple combination of interferon beta‐1b, om/journals/lancet/artic interferon beta‐1b, lopinavir–ritonavir, and ribavirin in the treatment of 08 May 2020 The Lancet RCT Hong Kong Hung et al. le/PIIS0140‐ NCT04276688 lopinavir–ritonavir, The efficacy and safety of combination patients admitted to hospital with COVID‐19: an open‐ ribavirin label, randomised, phase 2 trial 6736(20)31042‐ 4/fulltext https://www.thelancet.c Interleukin‐1 blockade with high‐dose anakinra in om/journals/lanrhe/artic The Lancet patients with COVID‐19, acute respiratory distress Observational 07 May 2020 Italy Cavalli et al. le/PIIS2665‐ NCT04318366 anakinra Efficacy of anakinra Rheumatology syndrome, and hyperinflammation: a retrospective study cohort study 9913(20)30127‐ 2/fulltext https://www.sciencedire Journal of Supportive Treatment with Tocilizumab for COVID‐19: Systematic ct.com/science/article/pi Outcomes associated with TCZ 19 April 2020 USA Alzghari et al. NA NA Clinical Virology A Systematic Review Review i/S1386653220301220?v treatment in patients with COVID‐19 ia%3Dihub https://www.clinicalmicr Umifenovir treatment is not associated with improved obiologyandinfection.co Retrospective Effectiveness and safety of umifenovir 25 April 2020 Microbiology and outcomes in patients with coronavirus disease 2019: A China N. Lian, et al. m/article/S1198‐ NA Umifenovir (Arbidol) CT for moderate COVID‐19 retrospective study 743X(20)30234‐ 2/fulltext https://www.ncbi.nlm.ni Is Baricitinib an effective drug for clinical Baricitinib therapy in COVID‐19: A pilot study on safety 16 April 2020 ournal of Infectio CT Italy Fabrizio Cantini, et al. h.gov/pmc/articles/PMC NA Baricitinib and respiratory improvement in and clinical impact 7177073/ moderate COVID19 patients? https://www.medrxiv.or Mandated Bacillus Calmette‐Guérin (BCG) vaccination growth curve g/content/10.1101/2020 Does BCG vaccination serve as a 04 May 2020 medRxiv USA Berg et al. N/A BCG vaccination predicts flattened curves for the spread of COVID‐19 analysis .04.05.20054163v5.full.p protective factor against COVID‐19 df regression https://www.medrxiv.or analysis Does TB Vaccination Reduce COVID‐19 Infection? No g/content/10.1101/2020 To assess the effectiveness of BCG 22 April 2020 medRxiv based on USA/ Japan Fukui et al. N/A BCG vaccination Evidence from a Regression Discontinuity Analysis .04.13.20064287v1.full.p vaccination against COVID‐19 observational data df https://www.medrxiv.or A Novel Protein Drug, Novaferon, as the Potential g/content/10.1101/2020 Novaferon, To determine the antiviral effects of 29 April 2020 medRxiv RCT China Fang Zheng et al. ChiCTR2000029496 Antiviral Drug for COVID‐19 .04.24.20077735v1.full.p Lopinavir/Ritonavir Novaferon for COVID‐19 df To summarise the data on all currently https://www.medrxiv.or tested treatment and prevention Review and methodological analysis of trials currently all treatment and Systematic g/content/10.1101/2020 options for COVID‐19, and to 01 May 2020 medRxiv testing treatment and prevention options for the novel Greece, France Fragkou et al. N/A preparation options for review .04.27.20080226v1.full.p methodologically analyse and evaluate coronavirus disease (COVID‐19) globally. covid‐19 df the quality of the registered interventional studies https://www.medrxiv.or Could hydroxychloroquine Hydroxychloroquine application is associated with a retrospective g/content/10.1101/2020 administration be beneficial in the 01 May 2020 medRxiv decreased mortality in critically ill patients with COVID‐ China Bo Yu et al. N/A Hydroxychloroquine analysis .04.27.20073379v1.full.p treatment of critically ill patients with 19 df COVID‐19? https://www.medrxiv.or To determine if anti‐hypertensive drugs Hypertension and Renin‐Angiotensin‐Aldosterone retrospective g/content/10.1101/2020 29 April 2020 medRxiv USA Ip et al. N/A anti‐hypertensive agents are harmful or beneficial to Covid‐19 System Inhibitors in Patients with Covid‐19 analysis .04.24.20077388v1.full.p patients with hypertension df https://www.medrxiv.or To evaluate the antiviral efficacy of Lopinavir‐ritonavir alone or combined with arbidol in retrospective g/content/10.1101/2020 lopinavir/ritonavir, lopinavir/ritonavir alone or combined 29 April 2020 medRxiv the treatment of 73 hospitalized patients with COVID‐ China Xiu Lan et al. N/A analysis .04.25.20079079v1.full.p arbidol with arbidol in the treatment of 19: a pilot retrospective study df hospitalized patients with COVID‐19. https://www.medrxiv.or Preliminary evidence from a multicenter prospective prospective To assess the efficacy and safety of g/content/10.1101/2020 04 May 2020 medRxiv observational study of the safety and efficacy of observational China Mingxing Huang et al. (ChiCTR2000029609 Chloroquine chloroquine with different doses in .04.26.20081059v1.full.p chloroquine for the treatment of COVID‐19 study COVID‐19 df https://www.medrxiv.or To evaluate the effects of QT Interval Prolongation and Torsade De Pointes in retrospective g/content/10.1101/2020 Hydroxychloroquine, Hydroxychloroquine/Azithromycin on 01 May 2020 medRxiv Patients with COVID‐19 treated with USA/Italy Chorin et al. N/A analysis .04.27.20074583v1.full.p Azithromycin the QT interval and the arrhythmic risk Hydroxychloroquine/Azithromycin df in patients with SARS‐CoV‐2 infection. https://www.medrxiv.or To assess and compare all nucleic acid‐ Performance & Quality Evaluation of Marketed COVID‐ diagnostic kit David Surace Kapitula g/content/10.1101/2020 01 May 2020 medRxiv China N/A qPCR Diagnostic test based COVID‐19 testing kits from quality 19 RNA Detection Kits evaluation et al. .04.25.20080002v1.full.p control perspectives df

https://www.medrxiv.or azithromycin, To determine the relative risk of drug‐ Risk of drug‐induced Long QT Syndrome associated chloroquine, favipiravir, induced Long QT Syndrome (LQTS) Systematic g/content/10.1101/2020 29 April 2020 medRxiv with the use of repurposed COVID‐19 drugs: a USA/Canada Michaud et al. N/A hydroxychloroquine, associated with SARS‐CoV‐2 (COVID‐19) review .04.21.20066761v2.full.p systematic review lopinavir/ritonavir, proposed repurposed drugs compared df remdesivir to well‐known torsadogenic compounds retrospective analysis, Bayesian https://www.medrxiv.or To evaluate the risk of overdose for Concentration‐dependent mortality of chloroquine in logostic g/content/10.1101/2020 chloroquine treatment or prevention 29 April 2020 medRxiv Thailand/ UK/ France Watson et al. N/A Chloroquine overdose regression, .04.24.20078303v1.full.p regimens currently being trialled in pharmacodyn df COVID19 amic modelling https://www.thelancet.c Remdesivir in adults with severe COVID‐19: a om/journals/lancet/artic Effect of remdesivir in COVID‐19 29 April 2020 The Lancet randomised, double‐blind, placebo‐controlled, RCT China Wang et al. le/PIIS0140‐ NCT04257656 remdesivir patients multicentre trial 6736(20)31022‐ 9/fulltext Academic A Rapid Systematic Review of Clinical Trials Utilizing https://onlinelibrary.wil Systematic Analyze current literature to find the 02 May 2020 Emergency Chloroquine and Hydroxychloroquine as a Treatment USA Chowdhury et al. ey.com/doi/abs/10.1111 NA NA review role of CQ and HCQ Medicine for COVID‐19. /acem.14005 https://www.medrxiv.or Clinical Efficacy of Intravenous Immunoglobulin intravenous To determine the clinical efficacy of retrospective g/content/10.1101/2020 20 April 2020 medRxiv Therapy in Critical Patients with COVID‐19: A China Ziyun Shao et al. N/A immunoglobulin (IVIG) intravenous immunoglobulin (IVIG) cohort study .04.11.20061739v2.full.p Multicenter Retrospective Cohort Study therapy therapy in COVID‐19 patients. df Chloroquine dosing recommendations for pharmacokin https://ascpt.onlinelibra To establish best‐evidence to inform Clin Pharmacol 22 April 2020 pediatric COVID‐19 supported by modeling and etic (PBPK) Netherlands Verscheijden et al. ry.wiley.com/doi/10.100 N/A Chloroquine pediatric Chloroquine doses for children Ther. simulation. model 2/cpt.1864 infected with COVID‐19 Effect of High vs Low Doses of Chloroquine https://jamanetwork.co Diphosphate as Adjunctive Therapy for Patients To evaluate the safety & efficacy of JAMA Network m/journals/jamanetwor 24 April 2020 Hospitalized With Severe Acute Respiratory Syndrome RCT Brazil Borba et al NCT04323527 Chloroquine different dosages of chloroquine in Open kopen/fullarticle/276549 Coronavirus 2 (SARS‐CoV‐2) Infection: A patients with severe COVID‐19. Randomized Clinical Trial. 9 A Randomized, Single‐blind, Group sequential, Active‐ https://www.medrxiv.or To evaluate the clinical efficacy and controlled Study to evaluate the clinical efficacy and g/content/10.1101/2020 21 April 2020 medRxiv RCT China Zhong et al. ChiCTR2000029851 α‐Lipoic acid (ALA) safety of α‐Lipoic acid (ALA) for critically safety of α‐Lipoic acid for critically ill patients with .04.15.20066266v1.full.p ill patients with COVID‐19. coronavirus disease 2019（COVID‐19） df To systematically retrieve and Rapid review https://www.medrxiv.or summarize the current evidence of the Effectiveness and Safety of Glucocorticoids to Treat 22 April 2020 medRxiv and meta‐ China Shuya Lu et al g/content/10.1101/2020 N/A Glucocorticoids effectiveness and safety of COVID‐19: A Rapid Review and Meta‐Analysis analysis .04.17.20064469v1 glucocorticoid therapy for patients with COVID‐19 https://www.medrxiv.or To assess the effectiveness of specific A systematic review of Anakinra, Tocilizumab, Systematic g/content/10.1101/2020 Anakinra, Tocilizumab, interleukin‐1 and ‐6 inhibitors for the 26 April 2020 MedRxiv Sarilumab and Siltuximab for coronavirus‐related UK Khan et al N/A review .04.23.20076612v1.full.p Sarilumab, Siltuximab treatment of coronavirus‐related infections df infections. https://www.cytodyn.co Preliminary m/newsroom/press‐ Southern California Patients Treated with Leronlimab results from releases/detail/415/sout 13 April 2020 Press release USA CytoDyn INC. NA leronlimab Could leronlimab be effective? for COVID‐19 under Emergency IND clinical trial hern‐california‐patients‐ treated‐with‐leronlimab‐ for Transplantation of ACE2‐ Mesenchymal Stem Cells Aging and http://dx.doi.org/10.143 ACE2‐mesenchymal Efficacy of MSC transplantation in COVID 28 February 2020 Improves the Outcome of Patients with COVID‐19 CT China Leng et al. ChiCTR2000029990 Disease 36/AD.2020.0228 stem cell patients Pneumonia Journal of https://onlinelibrary.wil Tocilizumab treatment in COVID‐19: a single center Observational What are treatment responses of TCZ in 26 March 2020 Medical China Luo et al. ey.com/doi/full/10.1002 NA tocilizumab experience study the COVID‐19 patients? Virology /jmv.25801

Association of Inpatient Use of Angiotensin Converting https://www.ahajournal Angiotensin‐converting To determine the association between Circulation Enzyme Inhibitors and Angiotensin II Receptor Blockers Observational enzyme inhibitors in‐hospital use of ACEI/ARB and all‐ 17 April 2020 China Zhang et al. s.org/doi/10.1161/CIRCR NA Research with Mortality Among Patients With Hypertension study (ACEIs) and Angiotensin cause mortality in COVID‐19 patients Hospitalized With COVID‐19 ESAHA.120.317134 receptor blockers (ARBs) with hypertension

Association of Renin‐Angiotensin System Inhibitors https://jamanetwork.co Angiotensin‐converting Asses the association between With Severity or Risk of Death in Patients With enzyme inhibitors ACEIs/ARBs and severity of illness and 23 April 2020 JAMA Case series China Juy Li, et al m/journals/jamacardiolo NA Hypertension Hospitalized for Coronavirus Disease (ACEIs) and Angiotensin mortality in patients with hypertension 2019 (COVID‐19) Infection inWuhan, China gy/fullarticle/2765049 receptor blockers (ARBs) hospitalized for COVID‐19 infection.

Acta https://www.sciencedire Potential therapeutic effects of dipyridamole in the Is treatment with dipyridamol clinically PrePrint Pharmaceutica RCT China Xiaoyan Liu, et al. ct.com/science/article/pi NA Dipyridamole severely ill patients with COVID‐19 effetive in severly ill COVID19 patients? Sinica B i/S2211383520305529

Benefits and Risks of Chloroquine and https://www.medrxiv.or Hydroxychloroquine in The Treatment of Viral meta‐analysis g/content/10.1101/2020 chloroquine/hydroxycho To evaluate the efficacy and safety of 18 April 2020 medRxiv China/ USA Jing Wang et al Diseases: A Meta‐Analysis of Placebo Randomized of RCTs .04.13.20064295v1.full.p roquine Chloroquine and hydroxychloroquine Controlled Trials df To assess the effectiveness of hand Physical interventions to interrupt or reduce the https://www.medrxiv.or systematic hygiene, surface disinfecting, and other spread of respiratory viruses. Part 2 ‐ Hand hygiene Saudi Arabia, g/content/10.1101/2020 20 April 2020 medRxiv review and Al‐Ansary NA hygiene interventions hygiene interventions in preventing or and other hygiene measures: systematic review and Australia, Canada .04.14.20065250v1.full.p meta‐analysis reducing the spread of illnesses from meta‐analysis. df respiratory viruses https://www.medrxiv.or To investigate the efficacy and safety of An experimental trial of recombinant human interferon Recombinant human g/content/10.1101/2020 recombinant human interferon alpha1b 17 April 2020 medRxiv alpha nasal drops to prevent coronavirus disease 2019 Clinical trial China Meng et al. NCT04320238 interferon‐alpha nasal .04.11.20061473v1.full.p (rhIFN‐α) nasal drops in healthy medical in medical staff in an epidemic area drops df staff to prevent COVID‐19. An exploratory randomized, controlled study on the https://www.medrxiv.or 23 March 2020, efficacy and safety of lopinavir/ritonavir or arbidol Lopinavir‐Ritonavir combination g/content/10.1101/2020 lopinavir/ritonavir updated 15 April medRxiv treating adult patients hospitalized with RCT China Li et al. NCT04252885 compared to Arbidol compared to no .03.19.20038984v2.full.p (Kaletra), arbidol 2020 mild/moderate COVID‐19 (ELACOI) antiviral treatment df https://www.medrxiv.or Potential Effectiveness and Safety of Antiviral Agents in To assess the potential effectiveness review and g/content/10.1101/2020 17 April 2020 medRxiv Children with Coronavirus Disease 2019: A Rapid China Shi et al. NA antivirals and safety of antiviral agents for COVID‐ meta‐analysis .04.13.20064436v1.full.p Review and Meta‐Analysis 19 in children. df https://www.medrxiv.or The aim of this review was to evaluate Efficacy and Safety of Antibiotic Agents in Children with g/content/10.1101/2020 17 April 2020 medRxiv rapid review China Wang et al NA antibiotics the efficacy and safety of antibiotic COVID‐19: A Rapid Review .04.13.20064402v1.full.p agents in children with COVID‐19 df No evidence of rapid antiviral clearance or clinical ben‐ https://www.sciencedire Médécine et Prospective Is hydroxychloroquine effecitve for viral efit with the combination of hydroxychloroquine and ct.com/science/article/pi Hydroxychloroquine, Preprint Maladies virological France JM Molina et al. NA clearance when reproducing the study azithromycin in patients with severe COVID‐19 i/S0399077X20300858?v azithromycin Infectieuses assay of Gautrel et al.? infection ia%3Dihub

Grant from the National Natural https://www.sciencedire Science Foundation The effect of corticosteroid treatment on patients with of China (Jing Liu, Accepted 31 Journal of ct.com/science/article/pi Evaluate the influence of corticosteroids coronavirus infection: a systematic review and meta‐ Meta‐analysis China Zhenwei Yang, et al. grant no. 81472735 Corticosteroids March 2020 Infection i/S0163445320301912?v in patients with coronavirus. analysis ) and the Wuhan ia%3Dihub University (Jing Liu, grant no. 2042019kf0206

Clinical https://academic.oup.co What is the best dose of Towards Optimization of Hydroxychloroquine Dosing in Prospective Preprint Infectious France Sophie Perinel et al, m/cid/article/doi/10.109 NA Hydroxychloroquine hydroxychloroquine for COVID19 Intensive Care Unit COVID‐19 Patients PK study Diseases 3/cid/ciaa394/5816960 patients? https://academic.oup.co Journal of Is cholorquine better than m/jmcb/article/doi/10.1 Chloroquine, lopinavir, Molecular Cell Treating COVID‐19 with Chloroquine RCT China Mingxing Huang, et al. NA lopinavir/ritonavir in severe and 093/jmcb/mjaa014/5814 ritonavir Biology moderate COVID19 patients? 655 https://www.nejm.org/d Compassionate Use of Remdesivir for Patients with UK, Canada, Europe, 10 April 2020 NEJM Report Grein et al. oi/full/10.1056/NEJMoa NA Remdesivir NA Severe Covid‐19 Japan 2007016 https://www.sciencedire Summary of the existing the evidence on Journal of A systematic review on the efficacy and safety of Systematic Andrea Cortegiani, et ct.com/science/article/pi 10 March 2020 Italy NA Chloroquine chloroquine for the treatment of COVID‐ Critical Care chloroquine for the treatment of COVID‐19 review al. i/S0883944120303907?v 19 ia%3Dihub Systematic review of the clinical Journal Systematic review of the efficacy and safety of https://onlinelibrary.wil Systematic outcomes of using antiretroviral drugs Preprint International antiretroviral drugs against SARS, MERS, or COVID‐19: Switzerland N Ford et al. ey.com/doi/10.1002/jia2 NA Antiretroviral drugs review for the prevention and treatment of AIDS Society initial assessment .25489 coronaviruses and planned clinical trials Ethics committees of Hainan General Investigate the effects of 6‐week Complementary Non‐ https://www.sciencedire Hospital and respiratory rehabilitation training on Respiratory rehabilitation in elderly patients with Respiratory 30 March 2020 Therapies in interventional China Kai Liu, et al. ct.com/science/article/pi Huanggang Central respiratory function, QoL, mobility and COVID‐19: A randomized controlled study rehabilitation training Clinical Practice RCT i/S1744388120304278 Hospital (approval psychological function in elderly numbers: 19758 and patients with COVID‐19 20200125)

Complementary Non‐ https://www.sciencedire Progressive muscle Investigate the effect of progressive Effects of progressive muscle relaxation on anxiety and 6 March 2020 Therapies in interventional China Kai Liu, et al. ct.com/science/article/pi NA relaxation (sleep muscle relaxation on anxiety and sleep sleep quality in patients with COVID‐19 Clinical Practice RCT i/S1744388120302784 therapy) quality of COVID‐19 patients https://www.medrxiv.or First Clinical Study Using HCV Protease Inhibitor g/content/10.1101/2020 Effect of danoprevir in moderate COVID‐ 24 March 2020 MedRxiv Danoprevir to Treat Naïve and Experienced CT China Chen et al. NCT04291729 danopevir/ritonavir .03.22.20034041v1.full.p 19 patients COVID‐19 Patients df The potential of low molecular weight heparin to https://www.medrxiv.or Retrospective 07 April 2020 MedRxiv mitigate cytokine storm in severe covid‐19 patients: a China Chen Shi et al. g/content/10.1101/2020 not found enoxaparin Efficacy of enoxaparin CT retrospective clinical study .03.28.20046144v2 No evidence of clinical efficacy of hydroxychloroquine https://www.medrxiv.or To assess the effectiveness of in patients hospitalised for COVID‐19 infection and Retrospective Matthieu Mahévas et g/content/10.1101/2020 14 April 2020 MedRxiv France NA Hydroxychloroquine Hydroxychloroquine in patients with requiring oxygen: results of a study using routinely analysis al. .04.10.20060699v1.full.p severe Covid‐19 collected data to emulate a target trial df Grants: National Science and Technology Major Project (2018ZX10711001, 2017ZX10103011, 2017ZX10204401), Sanming Project of Medicine in Shenzhen (SZSM201412003, SZSM201512005), China Postdoctoral Science Foundation https://jamanetwork.co Is plasma from convalescente patients Treatment of 5 critically ill patients with COVID‐19 with Observational (2019T120147, 27 March 2020 JAMA China C Shen, et al. m/journals/jama/fullarti Convalescent plasma beneficial for critically ill COVID19 convalescent plasma study 2018M641508), patients? cle/2763983 Shenzhen Science and Technology Research and Development Project (202002073000001), National Natural Science Foundation of China (81902058), Shenzhen Science and Technology Research and Development

Proceedings of the National Observational https://www.pnas.org/c Is treatment with convalescent plasma Academy of The feasibility of convalescent plasma therapy in 6 April 2020 /retrospectiv China Kai Duan et al ontent/early/2020/04/0 ChiCTR2000030048 Convalescent plasma safe and beneficial for COVID19 Sciences of the severe COVID‐19 patients: a pilot study e control patients? United States of 2/2004168117 America

Compare medical masks to N95 Influenza and Medical Masks vs N95 Respirators for Preventing https://onlinelibrary.wil respirators in preventing laboratory other Systematic Jessica J Bartoszko, et N95 respirators vs Preprint COVID‐19 in Health Care Workers ‐ A Systematic Canada ey.com/doi/pdf/10.1111 NA confirmed viral infection and respiratory Respiratory review al. surgical masks Review and Meta‐Analysis of Randomized Trials illness including coronavirus specifically Viruses /irv.12745 in health care workers.

https://www.cambridge. org/core/journals/disast er‐medicine‐and‐public‐ health‐ preparedness/article/ra ndomized‐trial‐of‐ Is attending one live training session or Disaster RANDOMIZED TRIAL OF INSTRUCTOR‐LED TRAINING instructorled‐training‐ watching video trainings over a month Medicine and VERSUS VIDEO LESSON IN TRAINING HEALTH CARE Training on personal Preprint RCT Denmark L Christensen et al versus‐video‐lesson‐in‐ NA more effective for training on downing Public Health PROVIDERS IN PROPER DONNING AND DOFFING OF protective equipment and doffing personal protective Preparedness PERSONAL PROTECTIVE EQUIPMENT training‐health‐care‐ providers‐in‐proper‐ equipment? donning‐and‐doffing‐of‐ personal‐protective‐ equipment/CF08F4727D A9D536883ECBFD04BC2 570

Journal of Performance of VivaDiagTM COVID‐19 IgM/IgG Rapid https://onlinelibrary.wil Diagnostic Diagnostic serological To assess an easy to perform serological Preprint Medical Test is inadequate for diagnosis of COVID‐19 in acute Italy Irene Cassantini et al. ey.com/doi/epdf/10.100 NA assay assay assay for diagnosis of COVID19 Virology patients referring to emergency room department 2/jmv.25800 DOI: 10.1128/JCM.0 0461‐20; Hospital Ethics Committee of Joural of https://jcm.asm.org/con Evaluation of Nucleocapsid and Spike Protein‐based Diagnostic the General Hospital Diagnostic serological Evaluate the diagnostic feasibility of two Preprint Clinical China Wanbing Liu, et al. tent/early/2020/03/27/J ELISAs for detecting antibodies against SARS‐CoV‐2 assay of the Central assay ELISA assays Microbiology CM.00461‐20 Theater Command 107 of the PLA ([2020]003‐1) Article originally Australian New published in Zealand Clinical To compare the efficacy of cloth masks A cluster randomised trial of cloth masks compared https://bmjopen.bmj.co medical masks, cloth 2015; authors BMJ Open RCT Australia /Vietnam MacIntyre CR et al. Trials Registry: to medical masks in hospital healthcare with medical masks in healthcare workers m/content/5/4/e006577 masks added comment ACTRN12610000887 workers on 30/03/2020 077. https://www.medrxiv.or Efficacy of hydroxychloroquine in patients with COVID‐ Assess the efficacy of 31 March 2020 MedRxiv RCT China Zhaowei Chen et al. g/content/10.1101/2020 ChiCTR2000029559 Hydroxychloroquine 19: results of a randomized clinical trial hydroxychloroquine .03.22.20040758v2

Clinical and microbiological effect of a combination of https://www.mediterran Assess the efficacy of hydroxychloroquine and azithromycin in 80 COVID‐19 ee‐infection.com/wp‐ Hydroxychloroquine, Preprint RCT France Gautret et al. NA hydroxychloroquine associated with patients with at least a six‐day follow up: an content/uploads/2020/0 Azithromycin azithromycin observational study 3/COVID‐IHU‐2‐1.pdf

An exploratory randomized, controlled study on the 23 March 2020 efficacy and safety of lopinavir/ritonavir or arbidol https://www.medrxiv.or Lopinavir‐Ritonavir combination lopinavir/ritonavir (preprint, not yet BMJ treating adult patients hospitalized with RCT China Li et al. g/content/10.1101/2020 NCT04252885 compared to Arbidol compared to no (Kaletra), arbidol peer‐reviewed) mild/moderate COVID‐19 (ELACOI) .03.19.20038984v1 antiviral treatment ChiCTR2000029939, ChiCTR2000029935, ChiCTR2000029899, ChiCTR2000029898, ChiCTR2000029868, ChiCTR2000029837, ChiCTR2000029826, Breakthrough: Chloroquine phosphate has shown https://www.jstage.jst.g Summary of ChiCTR2000029803, 10 Feb 2020 Biosci Trends apparent efficacy in treatment of COVID‐19 associated China Gao et al. o.jp/article/bst/14/1/14 Chloroquine Could chloroquine be effective? 15 CTs ChiCTR2000029762, pneumonia in clinical studies. _2020.01047/_article ChiCTR2000029761, ChiCTR2000029760, ChiCTR2000029740, ChiCTR2000029609, ChiCTR2000029559, and ChiCTR2000029542

https://www.cytodyn.co Preliminary m/newsroom/press‐ Three Additional Patients with Severe COVID‐19 not published results from releases/detail/401/thre 30 March 2020 Treated with Leronlimab in New York Medical Center USA CytoDyn Inc. NA Leronlimab Could leronlimab be effective? yet clinical trial e‐additional‐patients‐ Bringing the Total to 10 Patients with‐severe‐covid‐19‐ treated‐with https://www.medrxiv.or Favipiravir versus Arbidol for COVID‐19: A Randomized Conventional therapy + favipiravir or 27 March 2020 medRxiv RCT China Chang Chen et al. g/content/10.1101/2020 ChiCTR2000030254 Favipiravir, Arbidol Clinical Trial arbidol? .03.17.20037432v2 International Hydroxychloroquine and azithromycin as a treatment https://www.sciencedire Journal of EudraCT number Hydroxychloroquine, Role of hydroxychloroquine on 20 March 2020 of COVID‐19: results of an open‐label non‐randomized CT France Gautret et al. ct.com/science/article/pi Antimicrobial 2020‐000890‐25 Azithromycin respiratory viral loads clinical trial Agents i/S0924857920300996#! https://www.ncbi.nlm.ni A Trial of Lopinavir‐Ritonavir in Adults Hospitalized lopinavir/ritonavir Lopinavir‐Ritonavir combination 19 March 2020 N Engl J Med RCT China Cao et al. h.gov/pubmed/3218746 ChiCTR2000029308 with Severe Covid‐19. (Kaletra) compared to conventional therapy ? 4 https://www.sciencedire Arbidol combined with LPV/r versus LPV/r alone Journal of Retrospective ct.com/science/article/pi Lopinavir/ritonavir, Arbidol and lopinavir‐ritonavir 11 March 2020 against Corona Virus Disease 2019: A retrospective China Lisi Deng NA Infection cohort study i/S0163445320301134?v Arbidol compared to lopinavir‐ritonavir only? cohort study ia%3Dihub High‐flow nasal‐oxygenation‐ assisted fibreoptic https://bjanaesthesia.or What is the efficacy and safety of high‐ British Journal tracheal intubation in critically ill patients with COVID‐ g/article/S0007‐ High‐flow nasal flow nasal oxygenation during fibreoptic In press RCT China Cai‐Neng Wu et al. ChiCTR2000029658 of Anaesthesia 19 pneumonia: a prospective randomised controlled 0912(20)30135‐ oxygnation bronchoscopic intubation in critically ill trial 5/fulltext patients with COVID‐19? Chinese Journal 2020 Pre‐print Efficacy of lopinavir, ritonavir and Arbidol for the Retrospective http://rs.yiigle.com/yufa Lopinavir/ritonavir, Efficacy of lopinavir/ritonavir and of Infectious China Chen Jun et al. NA online treatment of new coronavirus pneumonia analysis biao/1182592.htm Arbidol arbidol Diseases, Journal of Zhejiang http://www.zjujournals. University A pilot study of hydroxychloroquine in treatment of com/med/CN/10.3785/j. Role of hydroxychloroquine on 2020 (Medical patients with common coronavirus disease‐19 (COVID‐ RCT China Chen Jun et al. NCT04261517 Hydroxychloroquine issn.1008‐ respiratory viral loads Science) 2020 19) , Vol. 49 Issue 9292.2020.03.03 (1) Assess the efficacy and safety of Meplazumab treats COVID‐19 pneumonia: an open‐ https://doi.org/10.1101/ meplazumab, a humanized anti‐CD147 2020 Pre‐print MedRxiv CT China Huijie Bian et al. NCT 04275245 Meplazumab labelled, concurrent controlled add‐on clinical trial 2020.03.21.20040691 antibody, as add‐on therapy in patients with COVID‐19 pneumonia.

Total